[
  "The coagulation cascade is a tightly regulated process that leads to the formation of a clot that stops bleeding. The key players in the cascade are the serine proteases thrombin, factor Xa, and factor IXa. Thrombin is formed by the action of the zymogen prothrombin on factor X. Factor IXa is formed by the cleavage of factor X by factor VIIIa. Factor X is activated by the complex of factor VIIIa and factor IXa. The activation of factor X by factor VIIIa and factor IXa is negatively regulated by antithrombin, a serpin that is activated by the heparin cofactor. The thrombin that is formed in the cascade activates platelets and converts fibrinogen to fibrin. The fibrin clot is stabilized by the clot-forming factor XIII. The thrombin that is formed also activates the protein C pathway, which inactivates factors Va and VIIIa. The inhibition of thrombin by antithrombin is accelerated by heparin. The inhibition of factor IXa by antithrombin is also accelerated by heparin. The inhibition of factor Xa by antithrombin is also accelerated by the protein C pathway. The protein C pathway is activated by the thrombin that is formed in the coagulation cascade. The thrombin that is formed in the cascade also activates platelets. The activation of platelets by thrombin is inhibited by the serpin protein C. The inhibition of thrombin by antithrombin is also accelerated by heparin. The inhibition of thrombin by antithrombin is also accelerated by heparin. The inhibition of factor Xa by antithrombin is also accelerated by heparin. The inhibition of factor IXa by antithrombin is also accelerated by heparin.",
  "The T cell receptor (TCR) complex is a multisubunit structure that is composed of at least two chains, the TCRalpha and TCRbeta chains, and two or three copies of the CD3gamma, CD3delta, CD3epsilon, CD3zeta, and CD24 chains. The TCR complex is associated with the tyrosine kinase Lck, which phosphorylates the CD3 chains and the associated ZAP-7 0 protein kinase. The phosphorylation of the CD3 chains leads to the recruitment of the protein tyrosine kinase ZAP7 0, which is activated by Lck and phosphorylates downstream targets. The activation of Lck and ZAP7 0 is regulated by the transmembrane protein CD4 and the related protein CD8. The interaction of the TCR with peptide-MHC complexes on the surface of an antigen-presenting cell leads to the activation of the T cell and the initiation of the immune response.",
  "The complement system is a major component of the innate immune system. It consists of more than 3 0 proteins and is activated by three different pathways: the classical pathway, the lectin pathway, and the alternative pathway. The classical pathway is activated by antibody-antigen complexes and by the lectin pathway by carbohydrate-binding proteins such as mannan-binding lectin (MBL) and the pentraxins. The alternative pathway is spontaneously activated by hydrolysis of C3. The activation of the complement system results in the formation of the membrane attack complex (MAC), which lyses bacteria and cells.",
  "The anti-inflammatory cytokine IL-10 is a key regulator of inflammation. IL-10 acts by binding to its receptor on the surface of macrophages and other cells, activating the JAK / STAT pathway and inducing the expression of anti-inflammatory genes. The enzyme heme oxygenase-1 (HO-1) is induced by IL-10 and has been implicated in the anti-inflammatory effects of IL-10. HO-1 degrades heme to produce carbon monoxide, iron, and biliverdin, which is rapidly reduced to bilirubin. Bilirubin is a potent antioxidant that may contribute to the anti-inflammatory effects of HO-1. The induction of HO-1 by IL-10 may also contribute to the anti-inflammatory effects of IL-10 by reducing the levels of free heme, which is pro-inflammatory. The induction of HO-1 by IL-10 may also contribute to the anti-inflammatory effects of IL-10 by inhibiting the production of reactive oxygen species. The induction of HO-1 by IL-10 may also contribute to the anti-inflammatory effects of IL-10 by increasing the levels of carbon monoxide, which has been shown to inhibit the production of pro-inflammatory cytokines by macrophages.",
  "The chemokine receptors CXCR4 and CCR5 are G protein-coupled receptors (GPCRs) that bind chemokines and trigger a variety of cellular responses. They are expressed on a variety of cell types, including T cells, monocytes, macrophages, and neurons. The CXCR4 receptor is involved in the immune response and the CCR5 receptor is involved in HIV infection. The CXCR4 receptor is also involved in the development of the nervous system. The CCR5 receptor is involved in the immune response and the development of the nervous system. The CXCR4 receptor is also involved in the development of the heart. The CCR5 receptor is involved in the immune response and the development of the heart. The CXCR4 receptor is also involved in the immune response and the development of the heart. The CCR5 receptor is also involved in the immune response and the development of the heart. The CXCR4 receptor is also involved in the development of the nervous system. The CCR5 receptor is also involved in the immune response and the development of the nervous system. The CXCR4 receptor is also involved in the immune response and the development of the heart. The CCR5 receptor is also involved in the immune response and the development of the heart. The CXCR4 receptor is also involved in the immune response and the development of the nervous system. The CCR5 receptor is also involved in the immune response and the development of the nervous system.",
  "The T cell receptor (TCR) is a multi-subunit complex that is expressed on the surface of T cells and is responsible for the recognition of antigen by T cells. The TCR is composed of two chains, the alpha and beta chains, each of which is associated with one of the three CD3 subunits. The CD3 subunits are responsible for the association of the TCR with the membrane and for the assembly of the TCR complex. The CD3 subunits are also responsible for the association of the TCR with the signaling molecules that are responsible for the activation of T cells. The TCR is responsible for the recognition of antigen by T cells and is responsible for the activation of T cells. The activation of T cells is initiated by the interaction of the TCR with antigen bound to the MHC molecule on the surface of an antigen presenting cell (APC). The interaction of the TCR with antigen results in the activation of the src kinases Lck and Fyn, which phosphorylate the immunoreceptor tyrosine-based activation motifs (ITAMs) on the CD3 subunits. The phosphorylation of the ITAMs results in the recruitment of the ZAP-7 0 kinase, which is also activated by phosphorylation. The activation of ZAP-7 0 results in the activation of the MAP kinase pathway and the activation of the transcription factor NF-AT. The activation of NF-AT results in the activation of the transcription of genes involved in T cell activation.",
  "The TCA cycle is a central metabolic pathway that produces reducing equivalents (NADH and FADH2) and energy (ATP). The cycle is initiated by the oxidative decarboxylation of acetyl-CoA to form citrate. The cycle is completed by the oxidative decarboxylation of isocitrate to form fumarate and the reduction of two molecules of each of these three-carbon compounds to produce one molecule each of NADH and FADH2. The cycle is also a major source of carbon skeletons used in biosynthesis. The cycle is carried out by a series of enzymes that are located in different mitochondrial compartments. The cycle is completed by the transfer of reducing equivalents from the mitochondrial matrix to the cytosol and back to the mitochondrial matrix. The transfer of reducing equivalents is accomplished by the transfer of acetyl-CoA from the TCA cycle to the glyoxylate cycle, which produces malate and acetyl-CoA. The acetyl-CoA is converted to citrate in the mitochondrial matrix by the action of citrate synthase. The transfer of reducing equivalents from the mitochondrial matrix to the cytosol is accomplished by the transfer of malate from the mitochondrial matrix to the cytosol by the action of malate dehydrogenase. The transfer of reducing equivalents from the cytosol to the mitochondrial matrix is accomplished by the transfer of fumarate from the cytosol to the mitochondrial matrix by the action of fumarate hydratase. The transfer of reducing equivalents from the mitochondrial matrix back to the mitochondrial matrix is accomplished by the transfer of succinate from the mitochondrial matrix to the cytosol by the action of succinate dehydrogenase. The transfer of reducing equivalents from the mitochondrial matrix back to the TCA cycle is accomplished by the transfer of acetyl-CoA from the TCA cycle to the glyoxylate cycle. The transfer of acetyl-CoA from the TCA cycle to the glyoxylate cycle is accomplished by the action of isocitrate lyase. The transfer of acetyl-CoA from the glyoxylate cycle to the TCA cycle is also accomplished by the transfer of malate from the glyoxylate cycle to the TCA cycle. The transfer of acetyl-CoA from the glyoxylate cycle to the TCA cycle is also accomplished by the transfer of succinyl-CoA from the glyoxylate cycle to the TCA cycle. The transfer of succinyl-CoA from the glyoxylate cycle to the TCA cycle is accomplished by the transfer of 2-oxoglutarate from the glyoxylate cycle to the TCA cycle. The transfer of succinyl-CoA from the glyoxylate cycle to the TCA cycle is also accomplished by the transfer of malate from the glyoxylate cycle to the TCA cycle. The transfer of acetyl-CoA from the glyoxylate cycle to the TCA cycle is accomplished by the transfer of citrate from the glyoxylate cycle to the TCA cycle. The transfer of acetyl-CoA from the glyoxylate cycle to the TCA cycle is also accomplished by the transfer of isocitrate from the glyoxylate cycle to the TCA cycle. The transfer of succinyl-CoA from the glyoxylate cycle to the TCA cycle is accomplished by the transfer of 2-oxoglutarate from the glyoxylate cycle to the TCA cycle. The transfer of acetyl-CoA from the glyoxylate cycle to the TCA cycle is also accomplished by the transfer of isocitrate from the glyoxylate cycle to the TCA cycle. The transfer of succinyl-CoA from the glyoxylate cycle to the TCA cycle is accomplished by the transfer of 2-oxoglutarate from the glyoxylate cycle to the TCA cycle.",
  "The cell cycle is a highly regulated sequence of events that leads to the division of a cell. The cell cycle is divided into four phases: Gap 1 (G1), Gap 2 (G2), Mitosis (M), and Gap 2 (G2). The G1 phase is the first gap phase in the cell cycle and is followed by the S phase, during which DNA replication occurs. The G2 phase is the gap between the S phase and mitosis. The M phase is the phase in which the cell divides. The transition between the G1 and S phases is regulated by the cyclin-dependent kinases (CDKs). The transition from the G2 to M phase is regulated by the CDC2 5 phosphatase. The transition from the G2 to M phase is regulated by the CDC2 5C phosphatase. The transition from the G1 to S phase is regulated by the cyclin-dependent kinases (CDKs). The CDKs are a family of serine / threonine kinases that are activated by binding to a cyclin subunit. The CDKs are inhibited by the binding of CDK inhibitors (CDKIs). The CDKIs include the INK4 family (p1 6INK4a, p1 5INK4b, p1 8INK4c, and p19INK4d), the Cip / Kip family (p2 1cip1, p2 7kip1, and p5 7KIP2), and the p90Rsk family (p153p190). The p16INK4a protein is encoded by the CDKN2A gene. The p15INK4b protein is encoded by the CDKN2B gene. The CDKN2C gene encodes the p19INK4d protein. The CDKN2D gene encodes the p27kip1 protein. The p19INK4d protein is also known as smad4. The p153p190protein is also known as p145p190. p153p190is also known as p190RhoGAP. The p153p190protein is a GTPase-activating protein (GAP) for the Rho family of GTPases. The Rho family of GTPases includes Rho, Rac, and Cdc 4 2. The Rho GTPases regulate the actin cytoskeleton and are involved in cell motility. The p153p190protein binds to the Rho GTPases and inhibits their activity. The p153p190protein also binds to the p145p190protein and inhibits its RhoGAP activity. The p153p190protein also binds to the p145p190protein and inhibits its p190RhoGAP activity. The p153p190protein also binds to the p190RhoGAP protein and inhibits its p190RhoGAP activity. The p153p190protein also binds to the p190RhoGAP protein and inhibits its p190RhoGAP activity. The p153p190protein also binds to the p190RhoGAP protein and inhibits its p190RhoGAP activity. The p153p190protein is phosphorylated by the p38 kinase. The p153p190protein is also phosphorylated by the CDC2 kinase. The p153p190protein is dephosphorylated by the CDC2 5 phosphatase. The CDC2 5 phosphatase is activated by the ATM kinase in response to DNA damage.",
  "The Rab GTPases are a large family of proteins that are involved in the regulation of intracellular vesicle transport. The Rab GTPases are localized to specific intracellular membranes and are activated by specific guanine nucleotide exchange factors (GEFs) and inactivated by specific GTPase activating proteins (GAPs). The activated Rab proteins interact with specific effector proteins to regulate vesicle transport. The Rab GTPases are involved in the regulation of vesicle transport between the endoplasmic reticulum (ER) and the Golgi apparatus, the transport between Golgi apparatus and the plasma membrane, the transport between early and late endosomes, the transport between late endosomes and lysosomes, and the transport between the trans-Golgi network (TGN) and the plasma membrane. The Rab GTPases are involved in the regulation of vesicle transport between the ER and the Golgi apparatus, the transport between Golgi apparatus and the plasma membrane, the transport between late endosomes and lysosomes, and the transport between the TGN and the plasma membrane. The Rab GTPases are involved in the regulation of vesicle transport between the ER and the Golgi apparatus, the transport between Golgi apparatus and the plasma membrane, the transport between late endosomes and lysosomes, and the transport between trans-Golgi network and the plasma membrane. The Rab GTPases are involved in the regulation of vesicle transport between the ER and the Golgi apparatus, the transport between Golgi apparatus and the plasma membrane, the transport between late endosomes and lysosomes, and the transport between trans-Golgi network and the plasma membrane. The Rab GTPases are involved in the regulation of vesicle transport between the ER and the Golgi apparatus, the transport between Golgi apparatus and the plasma membrane, the transport between late endosomes and lysosomes, and the transport between trans-Golgi network and the plasma membrane. The Rab GTPases are involved in the regulation of vesicle transport between the ER and the Golgi apparatus, the transport between Golgi apparatus and the plasma membrane, the transport between late endosomes and lysosomes, and the transport between trans-Golgi network and the plasma membrane.",
  "Killer cell lectin like receptors (KLR) are a family of cell surface receptors expressed by NK cells, T cells, and other leukocytes. KLR are structurally diverse and include C-type lectin-like receptors, immunoglobulin-like receptors, and CD9 4 / NKG2 receptors. KLR are involved in the regulation of NK cell and T cell function and are important in the recognition of normal and transformed cells. The C-type lectin-like receptors include CD9 4 / NKG2 receptors and the NKG2D receptor. The immunoglobulin-like receptors include the Ly-4 9 receptors and the NKR-P1 receptors. The CD9 4 / NKG2 receptors are heterodimers of a C-type lectin-like subunit and an NKG2-like polypeptide. The NKG2-like polypeptide is encoded by the NKG2DC gene, which is a member of the NKG2 gene family. The NKG2-like polypeptide is encoded by the NKG2DL gene, which is a member of the NKG2 gene family. The Ly-4 9 receptors are homodimers of type II transmembrane glycoproteins. The Ly-4 9 receptors are encoded by a gene family that includes Ly-4 9, Ly4 9, and the Ly-4 9S2 gene. The CD9 4 / NKG2 receptors are inhibitory receptors that recognize MHC-I molecules on target cells. The Ly-4 9 receptors are activating receptors that recognize MHC-I molecules. The NKR-P1 receptors are activating receptors that recognize MHC-I molecules. The NKG2DC gene encodes the NKG2DC polypeptide, which associates with the NKG2-like polypeptide to form the NKG2DC / NKG2DL heterodimer. The NKG2DC / NKG2DL heterodimer is an activating receptor that recognizes MHC-I molecules. The NKG2DC / NKG2DL heterodimer is also an inhibitory receptor that recognizes MHC-I molecules.",
  "The complement system is a major part of the innate immune system and is involved in the opsonization of foreign particles, activation of the inflammatory response, and lysis of foreign cells. The complement system is activated by three pathways: the classical pathway, the alternative pathway, and the lectin pathway. The classical pathway is activated by the binding of C1q to an antigen-antibody complex. The alternative pathway is activated by the spontaneous hydrolysis of C3 to C3 (H2O). C3 (H2O) binds to factor B and factor B is cleaved by factor D to C3 (H2O) Bb. C3 (H2O) Bb is a C3 convertase that cleaves C3 to C3a and C3b. C3b binds to factor B to form the C5 convertase C3bBb. C5 convertase cleaves C5 to C5a and C5b. C5b binds to C6, C7, C8, and C9 to form the membrane attack complex (MAC). The lectin pathway is activated by the recognition of carbohydrates on foreign cells by mannose-binding lectin (MBL), ficolins, and collectin-1 1. The MBL-associated serine proteases (MASP-1 and MASP-2) cleave C2 and C4 to form the C3 convertase. The MASP-2-dependent lectin pathway is the most important complement pathway in humans.",
  "Inflammasomes are multiprotein complexes that regulate the activation of caspase-1 and the maturation and release of IL-18. Inflammasomes are activated by a variety of stimuli, including bacterial components, uric acid, ATP, and amyloid-beta. Inflammasome activation leads to the production of proinflammatory cytokines IL-18 and IL-1beta, and the induction of pyroptosis.",
  "The protease-activated receptors (PARs) are a family of G protein-coupled receptors that are activated by proteolytic cleavage of the N-terminal extracellular domain of the receptor. The tethered ligand is a new N-terminus that binds to the body of the receptor to activate the receptor. The four PARs in mammals are activated by the serine protease thrombin, but the PAR-2 receptor is also activated by the protease factor II (FII). The PAR-1 receptor is activated by proteases such as trypsin and tryptase, but not by thrombin. The PAR-2 receptor is activated by trypsin and factor Xa, but not by thrombin. The PAR-3 receptor is activated by trypsin and factor Xa, but not by thrombin. The PAR-4 receptor is activated by trypsin and factor Xa, but not by thrombin. The PAR-1 and PAR-3 receptors are activated by proteases that are generated at sites of tissue injury and inflammation. The PAR-2 receptor is activated by proteases that are generated during blood coagulation. The PAR-4 receptor is activated by trypsin and mast cell tryptase. The activation of PARs by proteases leads to a rapid increase in intracellular calcium levels and activation of G protein-coupled signaling pathways. The PAR-1 and PAR-2 receptors are coupled to the activation of the Gq protein, which leads to the activation of phospholipase C and the generation of inositol-1, 4, 5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 binds to its receptor in the endoplasmic reticulum, releasing calcium ions from intracellular stores. DAG activates protein kinase C (PKC), which can lead to the activation of the MAP kinase pathway. The PAR-3 receptor is coupled to the Gi protein, leading to the activation of the PI3 kinase pathway. The PAR-4 receptor is coupled to the G1 2 / 1 3 protein, leading to the activation of the Rho-associated kinase (ROCK) and the formation of stress fibers and focal adhesions.",
  "The insulin receptor is a tyrosine kinase receptor that is activated by binding of insulin or insulin-like growth factor-1 (IGF-1) to the receptor. The receptor is a heterodimer of two subunits, alpha and beta. The alpha subunit is extracellular and the beta subunit is intracellular. The beta subunit contains the tyrosine kinase domain and the tyrosine phosphorylation sites. The tyrosine phosphorylation sites are the binding sites for signaling molecules that are activated by the receptor. The tyrosine phosphorylation sites are phosphorylated by the receptor and the activated receptor phosphorylates the insulin receptor substrate (IRS) proteins. The IRS proteins are phosphorylated by the receptor on tyrosine residues and the phosphorylated IRS proteins bind to and activate the p8 5 subunit of PI3 kinase. PI3 kinase is activated by the receptor and phosphorylates lipids in the plasma membrane. The lipids in the plasma membrane activate the protein kinase AKT. AKT phosphorylates and inhibits glycogen synthase kinase 3 (GSK-3). GSK-3 phosphorylates and inhibits glycogen synthase, a key enzyme in glycogen synthesis. AKT also phosphorylates and activates the mTOR kinase. The mTOR kinase phosphorylates and activates the protein kinase S6K. S6K phosphorylates the ribosomal protein S6 and activates protein synthesis. The mTOR kinase also phosphorylates and activates the elF4B protein. The mTOR kinase also phosphorylates and activates the protein kinase PHLPP. PHLPP dephosphorylates and inactivates the protein kinase Akt.",
  "The immune system is a complex network of cells and molecules that protect the body against foreign pathogens and tumor cells. The immune system is divided into two parts, the innate and the adaptive immune systems. The innate immune system is the first line of defense against foreign pathogens and is present in all animals. The adaptive immune system is acquired by the immune system and is more specific in its response to foreign antigens. The innate immune system includes natural killer cells, macrophages, neutrophils, and dendritic cells. The adaptive immune system includes T cells and B cells. The adaptive immune system is more specific in its response to foreign antigens. The adaptive immune system is acquired by the immune system and is more specific in its response to foreign antigens. The adaptive immune system is also more complex than the innate immune system. The adaptive immune system is divided into two types, the T cell and B cell immune systems. T cells are lymphocytes that respond to antigen stimulation by proliferating and differentiating into two types of T cells, helper T cells and cytotoxic T cells. Cytotoxic T cells are responsible for destroying cells that express foreign antigens on their surface. Helper T cells are responsible for stimulating the immune response by activating other immune cells. B cells are lymphocytes that produce antibodies. Antibodies are secreted by B cells that bind to foreign antigens and activate the immune response.",
  "Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-beta (TGF-beta) superfamily of secreted growth factors. BMPs are involved in a variety of developmental processes, including bone formation, neural induction, and patterning of the mesoderm. BMPs also play a role in the regulation of cell proliferation, apoptosis, and differentiation. BMPs are secreted proteins that bind to cell surface receptors and activate SMAD-dependent and SMAD-independent signaling pathways. SMAD-dependent signaling is activated by the binding of BMPs to type I and type II BMP receptors. The type II receptor phosphorylates and activates the type I receptor, which in turn phosphorylates the receptor-regulated SMADs (R-SMADs). The R-SMADs then associate with the co-SMAD, SMAD4, and translocate to the nucleus where they regulate transcription of target genes. SMAD-independent signaling is activated by BMP binding to the type I receptor, which activates the small G protein RAS and the MAP kinase pathway.",
  "The opioid peptide dynorphin is a neurotransmitter and neuromodulator in the central nervous system. Dynorphin is released from neurons in the basal ganglia and is involved in the regulation of motor activity, pain perception, and learning and memory. Dynorphin is also involved in the development of drug tolerance and dependence. Dynorphin is a peptide that is cleaved from the prodynorphin precursor by the protease, dynorphin converting enzyme (DECE1). Dynorphin binds to the kappa opioid receptor (KOR) to activate G-protein coupled signaling pathways. KOR activation leads to inhibition of adenylyl cyclase and inhibition of cAMP production. KOR activation also leads to activation of the MAP kinase pathway and activation of the transcription factor, AP-1. The dynorphin peptide is also cleaved by the protease, neprilysin, to produce the opioid peptides, met-enkephalin, leu-enkephalin, and beta-endorphin. These peptides activate the mu opioid receptor (MOR) and the delta opioid receptor (DOR) to inhibit adenylyl cyclase and activate the MAP kinase pathway. The activation of the MAP kinase pathway by the opioid peptides leads to activation of the transcription factor, AP-1. The activation of AP-1 by the opioid peptides may play a role in the development of drug tolerance and dependence.",
  "The Notch signaling pathway is a highly conserved intercellular signaling mechanism that plays a key role in cell fate determination and cell proliferation. The Notch receptor is a single-pass transmembrane protein that is activated by binding of a Delta or Jagged ligand on an adjacent cell. Ligand binding induces proteolytic cleavage of the Notch receptor, releasing the Notch intracellular domain (NICD). The NICD translocates to the nucleus and forms a complex with the DNA binding protein CSL (CBF1 / Su (H) / Lag1). This complex activates transcription of Notch target genes, including members of the Hes and Hey families. Notch signaling is involved in many developmental processes, including neurogenesis, myogenesis, and vasculogenesis. Notch signaling is also involved in tumorigenesis, and activating mutations in Notch have been identified in a variety of human cancers.",
  "The GPI anchor is a post-translational modification of proteins that tethers them to the membrane of the cell. The anchor is a common structure that is attached to proteins in a co-translational manner by a series of reactions that are conserved from yeast to humans. The anchor is a complex oligosaccharide that is attached to the carboxyl-terminus of proteins by a peptide bond. The first step in the pathway is the addition of N-acetylglucosamine (GlcNAc) to phosphatidylinositol (PI) to form GlcNAc-PI. In mammals, the second step is the addition of a phosphoethanolamine (P-EtN) group to the inositol ring to form N-acyl-Ethanolamine-Phosphate-Decaprenyl-GlcNAc-PI (GlcNAc-PI). The third step is the addition of a preformed phosphoethanolamine-phosphate (P-EtN-P) group to the inositol ring to form N-acyl-Ethanolamine-Phosphate-Inositol-Ethanolamine-Phosphate-Decaprenyl-GlcNAc-PI (Etn14GlcN-PI). The fourth step is the addition of a preformed diacylglycerol (DAG) group to the inositol ring to form Ethanolamine-Phosphate-Inositol-DAG (Etn14GlcN-PI-DAG). The fifth step is the addition of a preformed phosphoethanolamine (P-EtN) group to the inositol ring to form Ethanolamine-Phosphate-Inositol-DAG (Etn14GlcN-PI-DAG). The sixth step is the addition of a preformed phosphoethanolamine (P-EtN) group to the inositol ring to form Ethanolamine-Phosphate-Inositol-DAG (Etn14GlcN-PI-DAG). The seventh step is the addition of a preformed phosphoethanolamine (P-EtN) group to the inositol ring to form Ethanolamine-Phosphate-Inositol-DAG (Etn14GlcN-PI-DAG). The eighth step is the addition of a preformed phosphoethanolamine (P-EtN) group to the inositol ring to form Ethanolamine-Phosphate-Inositol-DAG (Etn14GlcN-PI-DAG). The ninth step is the addition of a preformed phosphoethanolamine (P-EtN) group to the inositol ring to form Ethanolamine-Phosphate-Inositol-DAG (Etn14GlcN-PI-DAG). The tenth step is the addition of a preformed phosphoethanolamine (P-EtN) group to the inositol ring to form Ethanolamine-Phosphate-Inositol-DAG (Etn14GlcN-PI-DAG). The eleventh step is the addition of a preformed phosphoethanolamine (P-EtN) group to the inositol ring to form Ethanolamine-Phosphate-Inositol-DAG (Etn14GlcN-PI-DAG). The twelfth step is the addition of a preformed phosphoethanolamine (P-EtN) group to the inositol ring to form Ethanolamine-Phosphate-Inositol-DAG (Etn14GlcN-PI-DAG).",
  "The immune system is composed of two major cell types, lymphocytes and phagocytes. The lymphocytes are classified into two major lineages, the T cells and the B cells. The T cells are further subdivided into helper T cells (Th) and cytotoxic T cells (Tc). The B cells are further subdivided into antibody-secreting B cells (B cells) and memory B cells (Bmem). The phagocytes are also classified into two major lineages, the granulocytes (neutrophils, eosinophils, basophils, and mast cells) and the mononuclear phagocytes (macrophages, monocytes, and dendritic cells). The T cells and B cells are activated by antigen-presenting cells (APCs). The APCs are classified into two types, the dendritic cells (DCs) and the macrophages. The DCs are the most potent APCs and are responsible for the induction of primary immune responses. The macrophages are responsible for the induction of innate immunity and the maintenance of tissue homeostasis. The activation of T cells and B cells is triggered by the recognition of antigen by the T cell receptor (TCR) and the B cell receptor (BCR), respectively. The activation of T cells and B cells is also triggered by the interaction of the TCR and the costimulatory molecules. The activation of T cells and B cells is also regulated by the cytokines produced by the APCs.",
  "G protein-coupled receptors (GPCRs) are a large family of cell surface receptors that respond to a variety of extracellular stimuli. The GPCR family is the largest group of cell surface receptors, with more than 8 0 0 members in the human genome. GPCRs are activated by a variety of stimuli, including hormones, neurotransmitters, odorants, light, and ions. Upon activation, GPCRs interact with G proteins, which in turn activate a variety of downstream signaling pathways. One of the most important pathways activated by GPCRs is the mitogen-activated protein kinase (MAPK) cascade. The MAPK cascade is a highly conserved module of three kinases that includes a MAPK kinase kinase (MAPKKK), a MAPK kinase (MAPKK), and a MAPK. The MAPKKK phosphorylates and activates the MAPKK, which in turn phosphorylates and activates the MAPK. The MAPK family is involved in a variety of cellular processes, including proliferation, differentiation, and apoptosis. The MAPK pathways are activated by a variety of stimuli, including growth factors, cytokines, and stress stimuli. The MAPK cascade is activated by a variety of mechanisms, including phosphorylation of the MAPKKK by MAPKKK kinases, interaction with adaptor proteins, and interaction with small G proteins. The MAPKKK family is large and includes the Raf, MEK, and ASK1 kinases. The MAPKKK activates the MAPKK, which in turn activates the MAPK. The MAPKKK family includes the MEKK1, MEKK2, MEKK3, and MEKK4 kinases. The MAPKK family is large and includes the MEK1, MEK2, and MEK5 kinases. The MAPK family is large and includes the ERK1, ERK2, ERK3, ERK5, JNK1, JNK2, and JNK3 kinases. The MEKK1, MEKK2, MEKK3, and MEKK4 kinases activate the JNK pathway, while the ASK1 kinase activates the p3 8 pathway. The MEKK1, MEKK2, MEKK3, and MEKK4 kinases are activated by the small G protein Ras, while the ASK1 kinase is activated by the small G protein ASK1. The Raf kinase is a MAPKKK that activates the MEK kinase, which in turn activates the ERK1 and ERK2 kinases. The Raf kinase is activated by the small G protein Ras, while the MEK kinase is activated by the kinase Byr2. The Byr2 kinase is activated by the small G protein RhoA. The MEKK1 kinase is activated by the small G protein Rac1. The Byr2 kinase is activated by the small G protein Cdc4 2.",
  "The interleukin-2 receptor (IL-2R) is a heterodimer of alpha and beta chains. The IL-2R\u03b1 chain is also known as the Tac antigen, CD2 5. The IL-2R\u03b1 chain is the target of the monoclonal antibody daclizumab, which is used to treat autoimmune disorders and prevent organ rejection. The IL-2R\u03b1 chain is also the target of the recombinant IL-2 fusion protein, aldesleukin, which is used to treat cancer. The IL-2R\u03b2 chain is shared with the IL-4 receptor and is also the target of daclizumab. The IL-2R\u03b2 chain is also shared with the IL-7 receptor and is the target of the monoclonal antibody imunoglobulin-1 (basiliximab) used to treat autoimmune disorders. The IL-2R\u03b1 chain is also the target of the monoclonal antibody basiliximab. The IL-2R\u03b1 chain is also the target of the IL-2 fusion protein, aldesleukin. The IL-2R\u03b1 chain is also the target of the monoclonal antibody basiliximab. The IL-2R\u03b2 chain is also the target of the monoclonal antibody daclizumab. The IL-2R\u03b1 chain is also the target of the recombinant IL-2 fusion protein, aldesleukin. The IL-2R\u03b1 chain is the target of the monoclonal antibody imunoglobulin-1 (basiliximab) used to treat autoimmune disorders. The IL-2R\u03b1 chain is also the target of the recombinant IL-2 fusion protein, aldesleukin. The IL-2R\u03b1 chain is also the target of the monoclonal antibody basiliximab. The IL-2R\u03b1 chain is also the target of the monoclonal antibody daclizumab. The IL-2R\u03b1 chain is also the target of the recombinant IL-2 fusion protein, aldesleukin. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, daclizumab. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, basiliximab. The IL-2R\u03b1 chain is also the target of the recombinant IL-2 fusion protein, aldesleukin. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, imunoglobulin-1 (basiliximab). The IL-2R\u03b1 chain is the target of the monoclonal antibody, daclizumab. The IL-2R\u03b1 chain is also the target of the recombinant IL-2 fusion protein, aldesleukin. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, basiliximab. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, daclizumab. The IL-2R\u03b1 chain is also the target of the recombinant IL-2 fusion protein, aldesleukin. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, imunoglobulin-1 (basiliximab). The IL-2R\u03b1 chain is also the target of the recombinant IL-2 fusion protein, aldesleukin. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, daclizumab. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, basiliximab. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, imunoglobulin-1 (basiliximab). The IL-2R\u03b1 chain is also the target of the recombinant IL-2 fusion protein, aldesleukin. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, daclizumab. The IL-2R\u03b1 chain is also the target of the recombinant IL-2 fusion protein, aldesleukin. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, imunoglobulin-1 (basiliximab). The IL-2R\u03b1 chain is also the target of the monoclonal antibody, daclizumab. The IL-2R\u03b1 chain is also the target of the recombinant IL-2 fusion protein, aldesleukin. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, imunoglobulin-1 (basiliximab). The IL-2R\u03b1 chain is also the target of the recombinant IL-2 fusion protein, aldesleukin. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, daclizumab. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, imunoglobulin-1 (basiliximab). The IL-2R\u03b1 chain is also the target of the monoclonal antibody, daclizumab. The IL-2R\u03b1 chain is also the target of the recombinant IL-2 fusion protein, aldesleukin. The IL-2R\u03b1 chain is also the target of the recombinant IL-2 fusion protein, aldesleukin. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, basiliximab. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, daclizumab. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, imunoglobulin-1 (basiliximab). The IL-2R\u03b1 chain is also the target of the monoclonal antibody, daclizumab. The IL-2R\u03b1 chain is also the target of the recombinant IL-2 fusion protein, aldesleukin. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, imunoglobulin-1 (basiliximab). The IL-2R\u03b1 chain is also the target of the monoclonal antibody, imunoglobulin-1 (daclizumab). The IL-2R\u03b1 chain is also the target of the monoclonal antibody, imunoglobulin-1 (basiliximab). The IL-2R\u03b1 chain is also the target of the recombinant IL-2 fusion protein, aldesleukin. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, daclizumab. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, daclizumab. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, imunoglobulin-1 (basiliximab). The IL-2R\u03b1 chain is also the target of the monoclonal antibody, imunoglobulin-1 (basiliximab). The IL-2R\u03b1 chain is also the target of the recombinant IL-2 fusion protein, aldesleukin. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, daclizumab. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, daclizumab. The IL-2R\u03b1 chain is also the target of the recombinant IL-2 fusion protein, aldesleukin. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, imunoglobulin-1 (basiliximab). The IL-2R\u03b1 chain is also the target of the monoclonal antibody, daclizumab. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, imunoglobulin-1 (basiliximab). The IL-2R\u03b1 chain is also the target of the recombinant IL-2 fusion protein, aldesleukin. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, imunoglobulin-1 (basiliximab). The IL-2R\u03b1 chain is also the target of the recombinant IL-2 fusion protein, aldesleukin. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, daclizumab. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, imunoglobulin-1 (basiliximab). The IL-2R\u03b1 chain is also the target of the monoclonal antibody, imunoglobulin-1 (basiliximab). The IL-2R\u03b1 chain is also the target of the recombinant IL-2 fusion protein, aldesleukin. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, daclizumab. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, daclizumab. The IL-2R\u03b1 chain is also the target of the recombinant IL-2 fusion protein, aldesleukin. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, imunoglobulin-1 (basiliximab). The IL-2R\u03b1 chain is also the target of the monoclonal antibody, imunoglobulin-1 (basiliximab). The IL-2R\u03b1 chain is also the target of the recombinant IL-2 fusion protein, aldesleukin. The IL-2R\u03b1 chain is also the target of the recombinant IL-2 fusion protein, aldesleukin. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, daclizumab. The IL-2R\u03b1 chain is the target of the recombinant IL-2 fusion protein, aldesleukin. The IL-2R\u03b1 chain is also the target of the monoclonal antibody, imunogam-1 (basiliximab). The IL-2R\u03b1 chain is also the target of the monoclonal antibody, daclizumab. The IL-2R\u03b1 chain is also",
  "Fas is a cell surface receptor that transduces apoptotic signals in response to Fas ligand binding. Fas-mediated apoptosis is initiated by the binding of Fas ligand to Fas, which recruits the adaptor protein FADD to the membrane. FADD recruits the protease caspase-8, which activates caspase-3 and other downstream caspases. The Fas-FADD-caspase-8 pathway is negatively regulated by the cellular FLICE-inhibitory protein (FLIP). The Fas-FADD-caspase-8 pathway can be activated by cytotoxic T cells and other immune cells. The Fas-mediated apoptotic pathway is also activated by chemotherapeutic agents and radiation.",
  "Transcriptional regulation of genes by steroid hormone receptors is a complex process that involves the interaction of the receptor with a variety of coactivators and corepressors. The coactivators include a variety of proteins that interact with the receptor to increase the transcriptional activity of the receptor. The corepressors include histone deacetylases that interact with the receptor to repress transcription. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators include p300, CBP, CBP-associated factor, steroid receptor RNA activator, and p200. The corepressors include histone deacetylases, NCoR, and SMRT. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of different ways. The coactivators and corepressors are involved in the regulation of transcription by steroid hormone receptors in a variety of ways. The coactivators and corepressors are involved in the regulation of transcription by steroid",
  "ErbB receptors are activated by a variety of ligands, including EGF, TGFalpha, heparin-binding EGF-like growth factor (HB-EGF), betacellulin (BTC), neuregulins (NRG), and heregulin (HRG). These ligands are synthesized as transmembrane precursors that are cleaved by proteases to release the soluble ligands. ErbB receptors are receptor tyrosine kinases that form homodimers and heterodimers. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are classified into three groups based on their ligand specificity. The first group includes ErbB1 (EGFR), ErbB2 (HER2), and ErbB4 (HER4). The second group includes ErbB3 (HER3) and Erb4 (HER4). The third group includes ErbB1 (EGFR) and ErbB2 (HER2). The first group binds EGF, TGFalpha, HB-EGF, BTC, and HRG. The second group binds TGFalpha and HRG. The third group binds NRGs. The ErbB receptors are activated by dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by EGF, TGFalpha, HB-EGF, BTC, neuregulins (NRG), and heregulin. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by EGF, TGFalpha, HB-EGF, BTC, neuregulins (NRG), and heregulin. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by EGF, TGFalpha, HB-EGF, BTC, neuregulins (NRG), and heregulin. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by EGF, TGFalpha, HB-EGF, BTC, neuregulins (NRG), and heregulin. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by EGF, TGFalpha, HB-EGF, BTC, neuregulins (NRG), and heregulin. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by EGF, TGFalpha, HB-EGF, BTC, neuregulins (NRG), and heregulin. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by EGF, TGFalpha, HB-EGF, BTC, NRG, and heregulin. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by EGF, TGFalpha, HB-EGF, BTC, neuregulins (NRG), and heregulin. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by EGF, TGFalpha, HB-EGF, BTC, neuregulins (NRG), and heregulin. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by EGF, TGFalpha, HB-EGF, BTC, neuregulins (NRG), and heregulin. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by EGF, TGFalpha, HB-EGF, BTC, neuregulins (NRG), and heregulin. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization. The ErbB receptors are activated by ligand-induced dimerization.",
  "Leptin is a hormone secreted by adipose tissue that regulates food intake and energy expenditure. Leptin binds to its receptor in the hypothalamus, activating the JAK / STAT pathway and increasing expression of the neuropeptide neuropeptide, proopiomelanocortin (POMC). POMC neurons project to the paraventricular nucleus (PVN) of the hypothalamus, stimulating the release of the satiety hormone, alpha-MSH. Leptin also acts on the NPY / AgRP neurons in the hypothalamus, inhibiting the release of the orexigenic peptide, NPY. Leptin also acts on the mesolimbic dopamine reward pathway to reduce the rewarding effects of food. The discovery of leptin and its receptor has led to the identification of a number of other factors that regulate food intake and energy expenditure. These factors include insulin, ghrelin, and the sympathetic nervous system.",
  "The epidermal growth factor receptor (EGFR) is a transmembrane receptor tyrosine kinase that is activated by binding of ligands such as EGF and transforming growth factor-alpha (TGF-alpha). EGFR activation leads to the activation of several signaling pathways, including the Ras / Raf / MEK / ERK pathway, the PI3K / AKT pathway, and the STAT pathway. These pathways are involved in cell proliferation, cell survival, and cell migration. EGFR overexpression and / or mutation has been implicated in the development and progression of a variety of human cancers.",
  "The Wnt family of secreted glycoproteins plays a key role in the development of many tissues and organs. Wnt proteins are secreted glycoproteins that bind to cell surface receptors of the Frizzled family. The Wnt / Frizzled signaling pathway is involved in the regulation of cell proliferation, differentiation, and apoptosis. Wnt proteins interact with Frizzled receptors to activate two distinct pathways, one involving the cytoplasmic protein Dishevelled and the other involving the cytoplasmic protein beta-catenin. The Wnt / Frizzled pathway leads to the accumulation of beta-catenin in the cytoplasm and its subsequent translocation to the nucleus. In the nucleus, beta-catenin interacts with the transcription factor TCF / LEF to activate the transcription of Wnt-responsive genes.",
  "The innate immune system is the first line of defense against invading pathogens. The innate immune system is comprised of a variety of cells, including macrophages, neutrophils, natural killer cells, and dendritic cells. Macrophages are the first line of defense against invading pathogens and are activated by the presence of pathogens through the recognition of pathogen-associated molecular patterns (PAMPs) by pattern recognition receptors (PRRs). The recognition of PAMPs by PRRs activates the innate immune response, which includes the production of cytokines and chemokines, the recruitment of inflammatory cells to the site of infection, and the activation of the adaptive immune response. The recognition of PAMPs by PRRs also activates the production of reactive oxygen species (ROS) and nitric oxide (NO), which are important for killing pathogens. The innate immune response is also activated by damage-associated molecular patterns (DAMPs), which are molecules released by damaged cells or tissues that activate the innate immune response. The innate immune response is also activated by cytokines, such as TNF-alpha and IL-1, which are released by activated macrophages and activate the innate immune response. The activation of the innate immune response is important for the activation of the adaptive immune response. The adaptive immune response is comprised of T cells, B cells, and antigen-presenting cells (APCs). T cells are activated by APCs that present antigen to T cells, and B cells are activated by T cells that recognize antigen. The adaptive immune response is important for the clearance of pathogens and the development of long-lasting immunity.",
  "The immune system is comprised of two major components, the innate and the adaptive immune systems. The innate immune system is the first line of defense against invading pathogens and is comprised of natural killer (NK) cells, macrophages, and neutrophils. The adaptive immune system is comprised of B cells and T cells and is responsible for the generation of antigen-specific antibodies. The adaptive immune system is comprised of two major subsets of T cells, T helper cells (Th) and T cytotoxic cells (Tc). The Th cells are further subdivided into Th1 and Th2 cells. Th1 cells are involved in cellular immunity and produce cytokines such as IFN-gamma and IL-2. Th2 cells are involved in humoral immunity and produce cytokines such as IL-4, IL-5, and IL-1 0. The B cells are further subdivided into two major subsets, the antibody-producing plasma cells and memory B cells. The antibody-producing plasma cells are responsible for the production of antibodies against foreign antigens. The memory B cells are responsible for the production of antibodies against previously encountered antigens. The activation of B cells requires two signals. The first signal is provided by the binding of the B cell receptor (BCR) to antigen. The second signal is provided by the interaction of the T cell receptor (TCR) with the MHC-peptide complex on the surface of the antigen-presenting cell (APC). The activation of B cells leads to the expression of activation markers such as MHC II, CD8 0, and CD8 6. The activation of B cells also leads to the differentiation of B cells into plasma cells. The differentiation of B cells into plasma cells requires the activation of the JAK / STAT pathway and the expression of Blimp-1. Plasma cells secrete antibodies into the blood stream and are responsible for the humoral immune response.",
  "The CD4 molecule is a cell surface glycoprotein that is expressed on helper T cells and is involved in the regulation of the immune response. The CD4 molecule is a member of the immunoglobulin gene superfamily and is structurally similar to the CD8 molecule. The extracellular domain of CD4 binds to the alpha chain of the T cell receptor (TCR) and to the MHC class II molecule. The cytoplasmic domain of CD4 associates with the src family tyrosine kinase p5 6lck. The interaction of CD4 with the TCR and MHC II molecules may be important in the activation of helper T cells. The interaction of CD4 with the src family kinases may also be involved in the activation of T cells.",
  "Asthma is a chronic inflammatory disease of the airways that is characterized by airway hyperresponsiveness, airway inflammation, and airway remodeling. The hallmark of asthma is airway hyperresponsiveness, which is caused by a combination of airway inflammation and airway remodeling. The inflammatory response in asthma is characterized by the recruitment and activation of inflammatory cells, including mast cells, eosinophils, and lymphocytes. The inflammatory response is also characterized by the production of cytokines and chemokines, such as IL-4, IL-5, IL-13, and eotaxin, which are involved in the recruitment and activation of inflammatory cells. The inflammatory response is also characterized by airway remodeling, which is caused by the proliferation of airway smooth muscle cells, the hypertrophy and hyperplasia of airway epithelial cells, and the deposition of extracellular matrix. The inflammatory response and airway remodeling are caused by the activation of multiple signaling pathways, including the JAK / STAT pathway, the NF-kappaB pathway, and the MAPK pathway.",
  "Retinoids are vitamin A derivatives that are essential for normal development and differentiation of many tissues. The active form of vitamin A, all-trans retinoic acid (atRA), is a ligand for two families of nuclear receptors, the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs). The RARs are ligand-dependent transcription factors that bind to retinoic acid response elements (RAREs) in the promoters of target genes. The RXRs are members of the steroid / thyroid hormone receptor gene family and heterodimerize with the RARs. The RXR-RAR heterodimer is the active form of the receptor and binds to RAREs as a heterodimer. The RXR-RAR heterodimer is a target for atRA and other retinoids. The RXR-RAR heterodimer is a target for the drug bexarotene, which is used to treat patients with cutaneous T-cell lymphoma. The RXR-RAR heterodimer is also a target for the synthetic retinoid TTNPB, which is used to treat patients with acute promyelocytic leukemia. The corepressors N-CoR and SMRT are recruited to the RAR-RXR heterodimer by the corepressors in the absence of ligand. Upon ligand binding, the corepressors are released and the coactivators are recruited to the receptor. The coactivators include histone acetyltransferases such as CBP / p30 0 and p16 0, and the histone methyltransferases CARM1 and Suvar3 9H1. The coactivators are required for transcriptional activation by the RXR-RAR heterodimer. The corepressors are also involved in transcriptional repression by the RXR-RAR heterodimer. The corepressors are released from the RXR-RAR heterodimer upon ligand binding, but the corepressors are not required for repression of the RXR-RAR heterodimer. The corepressors are involved in the repression of the RXR-RAR heterodimer by histone deacetylases (HDACs). The corepressors are also involved in the repression of the RXR-RAR heterodimer by the orphan receptor TR2. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor COUP-TF. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor COUP-TF. The corepressors are also involved in the repression of the RXR-RAR heterodimer by the orphan receptor TR2. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor COUP-TF. The corepressors are also involved in the repression of the RXR-RAR heterodimer by the orphan receptor TR2. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor COUP-TF. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor TR2. The corepressors are also involved in the repression of the RXR-RAR heterodimer by the orphan receptor COUP-TF. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor COUP-TF. The corepressors are also involved in the repression of the RXR-RAR heterodimer by the orphan receptor TR2. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor COUP-TF. The corepressors are also involved in the repression of the RXR-RAR heterodimer by the orphan receptor TR2. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor COUP-TF. The corepressors are also involved in the repression of the RXR-RAR heterodimer by the orphan receptor TR2. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor COUP-TF. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor TR2. The corepressors are also involved in the repression of the RXR-RAR heterodimer by the orphan receptor COUP-TF. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor COUP-TF. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor TR2. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor COUP-TF. The corepressors are also involved in the repression of the RXR-RAR heterodimer by the orphan receptor COUP-TF. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor TR2. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor COUP-TF. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor COUP-TF. The corepressors are also involved in the repression of the RXR-RAR heterodimer by the orphan receptor TR2. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor COUP-TF. The corepressors are also involved in the repression of the RXR-RAR heterodimer by the orphan receptor TR2. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor COUP-TF. The corepressors are also involved in the repression of the RXR-RAR heterodimer by the orphan receptor TR2. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor COUP-TF. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor COUP-TF. The corepressors are also involved in the repression of the RXR-RAR heterodimer by the orphan receptor TR2. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor COUP-TF. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor COUP-TF. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor TR2. The corepressors are also involved in the repression of the RXR-RAR heterodimer by the orphan receptor COUP-TF. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor TR2. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor COUP-TF. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor COUP-TF. The corepressors are also involved in the repression of the RXR-RAR heterodimer by the orphan receptor TR2. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor COUP-TF. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor TR2. The corepressors are also involved in the repression of the RXR-RAR heterodimer by the orphan receptor COUP-TF. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor COUP-TF. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor TR2. The corepressors are also involved in the repression of the RXR-RAR heterodimer by the orphan receptor COUP-TF. The corepressors are involved in the repression of the RXR-RAR heterodimer by the orphan receptor TR2. The corepressors are involved in the",
  "The metastatic cascade is a complex process that involves multiple steps. The first step is the local invasion of cancer cells into the surrounding tissue. This is followed by intravasation into the blood or lymphatic vessels, survival in the circulation, extravasation into the parenchyma of a distant organ, and colonization of the secondary site. The process of metastasis is regulated by a variety of genes. The expression of these genes is regulated by a variety of factors including hormones, growth factors, cytokines, and oncogenes. The expression of these genes is regulated by transcription factors. The transcription factors Snail, Slug, and Twist are involved in the epithelial-mesenchymal transition (EMT), a process that is involved in the invasion and metastasis of cancer cells. The transcription factor NF-kappaB is involved in the regulation of genes involved in the immune response, apoptosis, and metastasis. The transcription factor AP-1 is involved in the regulation of genes involved in the immune response and apoptosis. The transcription factor Egr-1 is involved in the regulation of genes involved in the immune response and apoptosis. The transcription factor Egr-1 is also involved in the regulation of genes involved in metastasis. The transcription factor AP-2 is involved in the regulation of genes involved in the immune response and apoptosis. The transcription factor Egr-1 is also involved in the regulation of genes involved in metastasis. The transcription factor Egr-1 is also involved in the regulation of genes involved in the immune response and apoptosis.",
  "The central nervous system (CNS) is separated from the rest of the body by the blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB). The BBB is formed by brain capillary endothelial cells (BCECs), which are joined by tight junctions (TJs). The BCSFB is formed by the choroid plexus epithelial cells (CPECs), which are joined by TJs. The BBB and BCSFB are formed by specialized endothelial cells, the brain capillary endothelial cells (BCECs). The tight junctions between BCECs are responsible for the impermeability of the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB) to most molecules. The BBB and BCSFB are essential for the homeostasis of the brain and the protection of the brain from harmful substances. The BBB and BCSFB are formed by specialized endothelial cells, the BCECs. The BBB and BCSFB are formed by specialized endothelial cells, the BCECs. The BCECs are joined by TJs. The BBB and BCSFB are essential for the homeostasis of the brain and the protection of the brain from harmful substances. The BCECs are joined by TJs. The BBB and BCSFB are formed by specialized endothelial cells, the BCECs. The BBB and BCSFB are essential for the homeostasis of the brain and the protection of the brain from harmful substances. The BBB and BCSFB are formed by specialized endothelial cells, the BCECs. The BCECs are joined by TJs. The TJs are composed of a group of proteins, including occludins, claudins, and junction adhesion molecules (JAMs). The BBB and BCSFB are essential for the homeostasis of the brain and the protection of the brain from harmful substances. The BBB and BCSFB are formed by specialized endothelial cells, the BCECs. The BCECs are joined by TJs. The BCECs are joined by TJs.",
  "The Eph receptor tyrosine kinase family is the largest family of receptor tyrosine kinases. Eph receptors are activated by their ligands, ephrins, which are also membrane bound. Eph receptors are divided into two groups, A and B, based on sequence homology and tissue distribution. The ephrin ligands are divided into two groups, A and B, based on sequence homology and tissue distribution. The ephrin-A ligands are GPI-linked membrane proteins, while the ephrin-B ligands are transmembrane proteins. The Eph receptors are activated by ephrin ligands, which induce receptor clustering and autophosphorylation. The activated Eph receptors then interact with other signaling molecules to transduce signals that affect cell shape, motility, and adhesion. The ephrin ligands are also activated by receptor-mediated signaling, and can signal in a forward direction through the Eph receptor, or in a reverse direction through interaction with ephrin ligands on adjacent cells. The ephrin-A ligands are expressed in a variety of tissues, while the ephrin-B ligands are expressed in a more limited set of tissues. The Eph receptors are expressed in a variety of tissues, but are most highly expressed in the nervous system. The ephrin ligands are also expressed in a variety of tissues, but are most highly expressed in the nervous system. The ephrin-A ligands are expressed in a variety of tissues, while the ephrin-B ligands are expressed in a more limited set of tissues. The Eph receptors and ephrin ligands are involved in a variety of developmental processes, including axon guidance, tissue boundary formation, and cell migration. The ephrin-B ligands are also involved in the migration of cancer cells.",
  "The T cell receptor (TCR) is a heterodimer of TCRalpha and TCRbeta chains that is expressed on the surface of T cells and recognizes peptide antigens presented by MHC molecules on the surface of antigen-presenting cells (APCs). The TCR is associated with the CD3 complex, which is composed of the CD3delta, CD3gamma, CD3epsilon, and CD3zeta chains. The TCRzeta chain is required for the formation of a functional TCR complex. The TCR is also associated with the CD28 molecule, which is required for the efficient activation of T cells. The TCR-CD3 complex is responsible for the recognition of antigen by T cells and the activation of T cells. The activation of T cells by antigen-presenting cells (APCs) is initiated by the interaction of the TCR with the peptide-MHC complex on the surface of the APC. This interaction leads to the activation of the TCR complex and the recruitment of additional TCR-CD3 complexes to the site of the TCR-peptide-MHC interaction. The activation of the TCR-CD3 complex leads to the activation of the tyrosine kinase Lck, which phosphorylates the immunoreceptor tyrosine-based activation motifs (ITAMs) in the CD3 chains. The phosphorylation of the ITAMs leads to the recruitment and activation of the tyrosine kinase ZAP7 0. The activation of Lck and ZAP7 0 leads to the activation of the downstream signaling pathways, including the Ras-Raf-MEK-ERK and the p38 pathways. The activation of these pathways leads to the activation of transcription factors such as NFAT and NF-kB, which are responsible for the induction of T cell activation and proliferation.",
  "Base excision repair (BER) is the major pathway for the repair of DNA damage caused by reactive oxygen species, alkylating agents, and other agents that modify DNA bases. BER is initiated by a DNA glycosylase that recognizes and excises a damaged base, leaving an abasic site. The abasic site is then repaired by the coordinated action of an AP endonuclease, a DNA polymerase, and a DNA ligase. The DNA glycosylases that initiate BER fall into two broad categories: (i) monofunctional DNA glycosylases that recognize and excise modified bases, and (ii) bifunctional DNA glycosylases that have an associated AP lyase activity that cleaves the DNA backbone at the abasic site. The monofunctional DNA glycosylases are found in all organisms and are responsible for the repair of the vast majority of spontaneous DNA damage. The bifunctional DNA glycosylases are found in bacteria and eukaryotes and are responsible for the repair of DNA damage caused by reactive oxygen species and alkylating agents. The bifunctional DNA glycosylases are also found in some bacteria and are involved in the repair of oxidative DNA damage. The repair of DNA damage caused by reactive oxygen species is initiated by the DNA glycosylase Fpg / Nei. The Nei DNA glycosylases are bifunctional DNA glycosylases that have an associated AP lyase activity that cleaves the DNA backbone at the abasic site. The repair of oxidative DNA damage is completed by the action of the DNA polymerase and DNA ligase.",
  "The retinoblastoma tumor suppressor gene (RB) encodes a nuclear phosphoprotein that is a negative regulator of cell cycle progression. The RB protein binds to the transcription factor E2F and represses transcription of genes required for S-phase entry. The phosphorylation of RB by the cyclin dependent kinases (CDKs) releases E2F, allowing transcription of genes required for S-phase entry. The cyclin dependent kinases are a family of protein kinases that are activated by association with cyclins. The cyclin D-dependent kinases (CDK4 and CDK6) are activated by cyclin D and phosphorylate RB. The cyclin E-dependent kinases (CDK2 and CDK3) are activated by cyclin E and phosphorylate RB. The CDK inhibitors (CDKIs) are negative regulators of the cell cycle that bind to and inhibit the cyclin-CDK complexes. The CDKI genes are induced by growth inhibitory signals and block cell cycle progression. The CDKIs include the p16INK4A, p15INK4B, p21Cip1 / Waf1, and p27Kip1 genes. The p16INK4A gene is induced by the tumor suppressor gene p53 and encodes a protein that binds to CDK4 and CDK6 to inhibit their kinase activity. The p15INK4B gene is induced by transforming growth factor-beta (TGF-beta) and inhibits the cyclin D-CDK4 / 6 complexes. The p21Cip1 / Waf1 gene is induced by the tumor suppressor gene p5 3 and encodes a protein that binds to and inhibits CDK2 and CDK3. The p27Kip1 gene is induced by TGF-beta and inhibits the cyclin E-CDK2 complex. The p15INK4B and p21Cip1 / Waf1 genes are induced by TGF-beta and inhibit the cyclin D-CDK4 / 6 and cyclin E-CDK2 complexes. The CDKIs are frequently inactivated in human cancer by deletion, mutation, or transcriptional repression. The p16INK4A gene is inactivated in many cancers by deletion or promoter methylation. The p15INK4B gene is inactivated by deletion or promoter methylation in some leukemias and lymphomas. The p21Cip1 / Waf1 gene is inactivated by deletion or promoter methylation in many leukemias and lymphomas. The p27Kip1 gene is inactivated by deletion or promoter methylation in many leukemias and lymphomas. The p15INK4B and p27Kip1 genes are also inactivated by deletion or promoter methylation in many solid tumors. The p16INK4A, p15INK4B, and p21Cip1 / Waf1 genes are also frequently inactivated by mutation in some leukemias and lymphomas. The p16INK4A, p15INK4B, and p21Cip1 / Waf1 genes are also inactivated by mutation in some solid tumors. The p16INK4A, p15INK4B, and p21Cip1 / Waf1 genes are also targets of transcriptional repression by the E2F-p10 7 complex. The p16INK4A, p15INK4B, and p21Cip1 / Waf1 genes are induced by the tumor suppressor gene p53 and are induced by TGF-beta. The p16INK4A, p15INK4B, and p21Cip1 / Waf1 genes are also induced by the tumor suppressor gene p53. The p16INK4A, p15INK4B, and p21Cip1 / Waf1 genes are also targets of transcriptional repression by the E2F-p10 7 complex. The p16INK4A, p15INK4B, and p21Cip1 / Waf1 genes are also targets of transcriptional repression by the E2F-p10 7 complex. The p16INK4A, p15INK4B, and p21Cip1 / Waf1 genes are also targets of transcriptional repression by the E2F-p10 7 complex. The p16INK4A, p15INK4B, and p21Cip1 / Waf1 genes are also targets of transcriptional repression by the E2F-p10 7 complex. The p16INK4A, p15INK4B, and p21Cip1 / Waf1 genes are also targets of transcriptional repression by the c-Myc-p10 7 complex. The p16INK4A, p15INK4B, and p21Cip1 / Waf1 genes are also targets of transcriptional repression by the E2F-p10 7 complex.",
  "The phosphorylation of DARPP-3 2 by PKA and CK1 is a key mechanism by which dopamine and other neurotransmitters regulate the activity of the protein phosphatase PP1. The phosphorylation of DARPP-3 2 by PKA and CK1 creates a potent inhibitor of PP1. The inhibition of PP1 by DARPP-3 2 is reversed by the action of protein phosphatase 2B (PP2B). The phosphorylation of DARPP-3 2 by PKA also activates the protein kinase cascade involving the kinases PKA, CK1 and GSK-3. The activation of GSK-3 by PKA and CK1 is reversed by the action of protein phosphatase 2A (PP2A).",
  "Insulin and IGF-1 stimulate glucose uptake in muscle and adipose tissue by stimulating translocation of the glucose transporter GLUT4 from intracellular vesicles to the plasma membrane. This translocation is mediated by the small G-protein Rab4 and its exchange factor, mSOS. The insulin receptor phosphorylates IRS-1, which then binds to the regulatory subunit of PI3-kinase. PI3-kinase phosphorylates the membrane lipid phosphatidylinositol-4, 5-bisphosphate (PIP2) to produce phosphatidylinositol-3, 4, 5-trisphosphate (PIP3). PIP3 binds to the PH domain of the exchange factor mSOS, causing it to release its inhibition by the N-terminal domain of mSOS. The release of mSOS activation allows it to activate Rab4, which in turn activates GLUT4 translocation. The activation of Akt by PI3-kinase also contributes to GLUT4 translocation. The activation of the MAP kinase pathway by PI3-kinase may also contribute to GLUT4 translocation.",
  "The cell cycle is a series of events that lead to the duplication of the genome and the division of the cell into two daughter cells. The cell cycle is driven by a family of protein kinases called cyclin-dependent kinases (CDKs). CDKs are activated by binding to a regulatory cyclin subunit, and the activity of CDKs is negatively regulated by CDK inhibitors. CDKs are inhibited by the CDK inhibitors p2 1Cip1 and p2 7Kip1, which are induced by DNA damage and other forms of stress. The activity of CDKs is also regulated by phosphorylation and dephosphorylation. The activity of CDKs is positively regulated by phosphorylation of a threonine residue in the catalytic domain (Thr-1 6 0 in CDK2) by CDK-activating kinases (CAK). The activity of CDKs is negatively regulated by phosphorylation of a tyrosine residue (Tyr-1 5 in CDK2) by the Wee1 kinase and dephosphorylation of this residue by the CDC2 5 phosphatase. The activity of Wee1 and CDC2 5 is regulated by phosphorylation and dephosphorylation by the Wee kinases and the p15Ink4b and p21Cip1proteins, respectively. The activity of CDKs is also regulated by the binding of CDK inhibitors (CKIs). CKIs are negative regulators of CDK activity. CKIs are induced by a variety of antiproliferative signals, including DNA damage, and inhibit the activity of CDKs to prevent cell cycle progression.",
  "The complement system is a major component of the innate immune system. The complement system is activated by the classical, lectin, and alternative pathways. The classical pathway is initiated by the recognition of antigen-antibody complexes by C1q. The lectin pathway is activated by the recognition of carbohydrate patterns on bacteria by mannose-binding lectin (MBL). The alternative pathway is activated by the recognition of foreign surfaces by properdin. The activation of the complement system leads to the formation of a membrane attack complex that lyses cells and releases inflammatory mediators. The complement system also plays an important role in the clearance of immune complexes and apoptotic cells. The opsonization of foreign cells by complement proteins enhances their phagocytosis by macrophages. The opsonization of apoptotic cells by complement proteins also enhances their recognition and removal by macrophages. The activation of the complement system leads to the generation of opsonins, such as C3b, C4b, and C3bi, and anaphylatoxins, such as C3a and C5a. The opsonins bind to complement receptors on macrophages and stimulate their phagocytosis of the opsonized cells. The anaphylatoxins stimulate the migration of leukocytes to the site of infection and stimulate the release of cytokines and other inflammatory mediators.",
  "The Rho family of GTPases are key regulators of the actin cytoskeleton. The Rho GTPases cycle between an inactive GDP-bound state and an active GTP-bound state. In the inactive state, Rho is bound to GDP-dissociation inhibitor (GDI). Activation of Rho is mediated by guanine nucleotide exchange factors (GEFs), which catalyze the exchange of GDP for GTP. GAPs stimulate the intrinsic GTPase activity of Rho, converting it to the inactive GDP-bound state. Guanine nucleotide dissociation inhibitors (GDIs) bind to the inactive form of Rho and keep it in the cytosol. In addition to their role in regulating Rho, GEFs and GAPs also act as signal transducers. GEFs activate Rho by stimulating the exchange of GDP for GTP, and GAPs inactivate Rho by stimulating the intrinsic GTPase activity of Rho. Guanine nucleotide exchange factors (GEFs) are a large family of proteins that are classified into four groups based on the presence of various functional domains. The Dbl family of GEFs contains a DH domain, which is responsible for GEF activity, and a PH domain, which is involved in the regulation of GEF activity and membrane localization. The Dbl family GEFs are regulated by various mechanisms, including phosphorylation, interaction with other proteins, and subcellular localization. The Dbl family GEFs also includes the Ect2 and Lfc proteins, which are involved in the regulation of cell cycle progression. The Lbc protein is involved in the development of leukemia. The Vav protein is involved in the development of lymphomas. The Dock1 8 0 protein is involved in the development of the immune system. The Dock2 and Dock5 proteins are involved in the development of the nervous system. The Crk adaptor protein is involved in the regulation of cell motility. The Crk adaptor protein is involved in the regulation of cell motility.",
  "TNF-alpha is a cytokine that induces apoptosis in a variety of cell types. The TNF-alpha receptor (TNFRSF1A) is a member of the TNF receptor gene family that includes the Fas receptor (TNFRSF6). The TNFRSF1A gene encodes a protein that is a member of the death receptor gene family. The TNFRSF1A protein contains a cytoplasmic death domain that is involved in apoptosis signaling. The TNFRSF1A gene is located on chromosome 1 2p1 3. 1. The TNFRSF1A gene is expressed as a 5 5 kDa protein that is cleaved to produce a soluble form of the receptor. The TNFRSF1A protein is expressed on the surface of a variety of cell types. The TNFRSF1A protein is a homotrimer. The TNFRSF1A protein is involved in apoptosis signaling. The TNFRSF1A protein is activated by binding TNF-alpha. The TNFRSF1A protein activates the transcription factor NF-kappa B, which is involved in the regulation of apoptosis and inflammation.",
  "The exosome is a conserved, multi-subunit complex that functions in RNA processing and degradation. The exosome is composed of a core complex and three associated factors. The core complex is a ring-shaped structure consisting of six RNase PH-like proteins (Rrp4 1, Rrp4 2, Rrp4 3, Rrp4 5, and Mtr3). The core complex is associated with two other proteins (Rrp4 and Rrp4 0). The exosome functions in the nucleus and cytoplasm to process rRNA, snoRNA, snRNA, and mRNA. The exosome also functions in the cytoplasm to degrade aberrant mRNAs and defective tRNAs. The exosome is a 3 '-5' exoribonuclease that degrades RNA in a 3 'to 5' direction. The exosome contains a 3 'to 5' exoribonuclease Rrp6, a 3 'to 5' exoribonuclease that is associated with the exosome core. The exosome also contains a 3 'to 5' endonuclease Rrp4 0. The exosome is involved in the processing of the 5 'external transcribed spacer (5' ETS) of rRNA, the 3 'end of the small nucleolar RNA (snoRNA), the 3' end of the U6 snRNA, and the 3 'end of the mRNA. The exosome also functions in the degradation of improperly processed and aberrant RNAs. The exosome is a complex of proteins that is highly conserved from bacteria to humans. The exosome is composed of a core complex and three associated factors. The core complex is composed of six RNase PH-like proteins (Rrp4 1, Rrp4 2, Rrp4 3, Rrp4 5, and Mtr3). The core complex is associated with two other proteins (Rrp4 and Rrp4 0). The Rrp6 exonuclease is associated with the core complex. The exosome contains a 3' to 5 'exoribonuclease Rrp6, a 3' to 5 'endonuclease Rrp4 0, and a Ski complex (Ski = superkiller, or SKI). The Ski complex is composed of three proteins (Ski2, Ski3, and Ski7). The exosome is involved in the processing of rRNA, the 3' end of the mRNA, and the degradation of improperly processed and aberrant RNAs. The exosome also functions in the cytoplasmic mRNA degradation pathway. The exosome is a complex of proteins that functions in RNA processing and degradation. The exosome is a complex of proteins that is highly conserved from bacteria to humans. The exosome is a complex of proteins that functions in RNA processing and degradation. The exosome is a complex of proteins that functions in RNA processing and degradation. The exosome is a complex of proteins that functions in RNA processing and degradation. The exosome is a complex of proteins that functions in RNA processing and degradation. The exosome is a 3 'to 5' exoribonuclease that degrades RNA in a 3 'to 5' direction. The exosome is a complex of proteins that functions in the processing of rRNA, the 3 'end of the mRNA, and the degradation of improperly processed and aberrant RNAs. The exosome is a complex of proteins that functions in the degradation of improperly processed and aberrant RNAs. The exosome is a complex of proteins that functions in the processing of rRNA, the 3' end of the mRNA, and the degradation of improperly processed and aberrant RNAs. The exosome is a complex of proteins that functions in the degradation of improperly processed and aberrant RNAs. The exosome is a complex of proteins that functions in the degradation of RNA in the cytoplasm. The exosome is a complex of proteins that functions in the processing of rRNA, the 3 'end of the mRNA, and the degradation of RNA. The exosome is a complex of proteins that functions in the degradation of RNA in the cytoplasm. The exosome is a complex of proteins that functions in the processing of rRNA, the 3' end of the mRNA, and the degradation of RNA. The exosome is a complex of proteins that functions in the degradation of RNA in the nucleus. The exosome is a complex of proteins that functions in the processing of rRNA, the 3 'end of the mRNA, and the degradation of RNA. The exosome is a complex of proteins that functions in the processing of rRNA, the 3' end of the mRNA, and the degradation of RNA. The exosome is a complex of proteins that functions in the degradation of RNA in the cytoplasm. The exosome is a complex of proteins that functions in the degradation of RNA. The exosome is a complex of proteins that functions in the degradation of RNA. The exosome is a complex of proteins that functions in the degradation of RNA. The exosome is a complex of proteins that functions in the degradation of RNA. The exosome is a complex of proteins that functions in RNA processing and degradation. The exosome is a complex of proteins that functions in the processing of rRNA, the 3 'end of the mRNA, and the degradation of RNA. The exosome is a complex of proteins that functions in the degradation of RNA. The exosome is a complex of proteins that functions in the processing of rRNA, the 3' end of the mRNA, and the degradation of RNA. The exosome is a complex of proteins that functions in the processing of rRNA, the 3 'end of the mRNA, and the degradation of RNA. The exosome is a complex of proteins that functions in the degradation of RNA. The exosome is a complex of proteins that functions in the processing of rRNA, the 3' end of the mRNA, and the degradation of RNA. The exosome is a complex of proteins that functions in the processing of rRNA, the 3 'end of the mRNA, and the degradation of RNA. The exosome is a complex of proteins that functions in the processing of rRNA, the 3' end of the mRNA, and the degradation of RNA. The exosome is a complex of proteins that functions in the processing of rRNA, the 3 'end of the mRNA, and the degradation of RNA. The exosome is a complex of proteins that functions in the degradation of RNA. The exosome is a complex of proteins that functions in the processing of rRNA, the 3' end of the mRNA, and the degradation of RNA. The exosome is a complex of proteins that functions in the degradation of RNA. The exosome is a complex of proteins that functions in the processing of RNA. The exosome is a complex of proteins that functions in the degradation of RNA. The exosome is a complex of proteins that functions in the processing of rRNA, the 3 'end of the mRNA, and the degradation of RNA. The exosome is a complex of proteins that functions in the processing of rRNA, the 3' end of the mRNA, and the degradation of RNA. The exosome is a complex of proteins that functions in the processing of rRNA, the 3 'end of the mRNA, and the degradation of RNA. The exosome is a complex of proteins that functions in the degradation of RNA. The exosome is a complex of proteins that functions in the processing of rRNA, the 3' end of the mRNA, and the degradation of RNA. The exosome is a complex of proteins that functions in the degradation of RNA. The exosome is a complex of proteins that functions in the degradation of RNA. The exosome is a complex of proteins that functions in the processing of rRNA, the 3 'end of the mRNA, and the degradation of RNA. The exosome is a complex of proteins that functions in the processing of rRNA, the 3' end of the mRNA, and the degradation of RNA. The exosome is a complex of proteins that functions in the processing of rRNA, the 3 'end of the mRNA, and the degradation of RNA. The exosome is a complex of proteins that functions in the processing of rRNA, the 3' end of the mRNA, and the degradation of RNA. The exosome is a complex of proteins that functions in the processing of rRNA, the 3 'end of the mRNA, and the degradation of RNA. The exosome is a complex of proteins that functions in the processing of rRNA, the 3' end of the mRNA, and the degradation of RNA. The exosome is a complex of proteins that functions in the processing of",
  "Platelet-derived growth factor (PDGF) is a potent mitogen for a variety of cell types. The PDGF receptor is a member of the receptor tyrosine kinase family. Binding of PDGF to the receptor stimulates receptor dimerization and autophosphorylation of several tyrosine residues in the cytoplasmic domain of the receptor. These phosphotyrosines serve as binding sites for SH2-containing signaling molecules, including the GRB2 adaptor protein, phospholipase C-gamma, the tyrosine phosphatase SHP-2, and the PI3 kinase. Activation of the PI3 kinase pathway leads to the activation of Akt and the downstream kinase, p38. Activation of the Ras / Raf / MEK / ERK pathway leads to the activation of the transcription factor AP-1.",
  "Apoptosis is a form of programmed cell death that is essential for normal development and tissue homeostasis. It is characterized by a series of morphological changes including cell shrinkage, membrane blebbing, chromatin condensation, and nuclear fragmentation. Caspases are a family of cysteine proteases that are responsible for the execution of apoptosis. Caspases are synthesized as inactive precursors and are activated by proteolytic cleavage. Caspases are organized into two groups: initiator caspases and effector caspases. The initiator caspases (caspase-2, -8, -9, and -1 0) are activated by specific adaptor proteins. The initiator caspases in turn activate the effector caspases (caspase-3, -6, and -7). The effector caspases cleave a variety of cellular proteins, leading to the morphological changes associated with apoptosis. Caspases are activated by two main apoptotic pathways: the extrinsic pathway and the intrinsic pathway. The extrinsic pathway is triggered by the binding of death receptors on the cell surface to their ligands, such as Fas ligand (FasL). The binding of FasL to Fas receptor recruits the adaptor protein FADD and caspase-8 to form the death-inducing signaling complex (DISC). The activation of caspase-8 in the DISC leads to the activation of the effector caspases, caspase-3 and -7, and the subsequent cleavage of cellular substrates. The intrinsic pathway is triggered by various stimuli, including DNA damage, growth factor withdrawal, and cytotoxic drugs, which lead to the release of cytochrome c from the mitochondria. Cytochrome c activates Apaf-1 and caspase-9 to form the apoptosome. The apoptosome activates caspase-3 and caspase-7.",
  "The T-cell receptor (TCR) is a multi-subunit complex that recognizes antigen bound to MHC molecules on the surface of antigen presenting cells. The TCR is composed of a heterodimer of alpha and beta chains that noncovalently associate with the CD3 complex. The CD3 complex is composed of three subunits (gamma, delta, epsilon, and zeta) that are associated in the order gamma-delta-epsilon-zeta. The zeta chain is responsible for the transduction of the TCR signal. The CD3 complex is responsible for the transduction of the TCR signal. The TCR signal is transduced through the src family kinase Lck and the Tec family kinase Itk. The TCR signal is transduced through the src family kinase Lck and the Tec family kinase Itk. The TCR signal is transduced through the src family kinase Lck and the Tec family kinase Itk. The TCR signal is transduced through the src family kinase Lck and the Tec family kinase Itk. The TCR signal is transduced through the tyrosine kinase ZAP7 0. The TCR signal is transduced through the tyrosine kinase ZAP7 0. The TCR signal is also transduced through the adaptor LAT. The TCR signal is transduced through the adaptor LAT. The TCR signal is transduced through the adaptor LAT. The TCR signal is transduced through the LAT signalosome. The LAT signalosome is composed of LAT, PLC-gamma, and the Tec family kinase Itk. The LAT signalosome is responsible for the downstream activation of the MAP kinase pathway. The TCR signal is also transduced through the LAT signalosome to activate the NF-AT pathway.",
  "The G protein-coupled receptor kinase 2 (GRK2) is a serine / threonine kinase that phosphorylates agonist-occupied G protein-coupled receptors (GPCRs) to desensitize GPCR signaling. GRK2 also interacts with beta-arrestins to mediate GPCR internalization. In addition to its role in GPCR desensitization, GRK2 has been shown to interact with a variety of signaling molecules to regulate cellular signaling pathways. The interaction of GRK2 with the peroxisome proliferator-activated receptor alpha (PPAR alpha) was identified in a yeast two-hybrid screen. The interaction of GRK2 with PPAR alpha was confirmed by coimmunoprecipitation and GST pull-down assays. The interaction of GRK2 with PPAR alpha was mapped to the amino-terminal domain of GRK2 and the ligand binding domain of PPAR alpha. The interaction of GRK2 with PPAR alpha did not affect the transcriptional activity of PPAR alpha. However, the interaction of GRK2 with PPAR alpha did inhibit the interaction of PPAR alpha with the transcriptional coactivator PGC-1. The interaction of GRK2 with PPAR alpha may play a role in the regulation of cellular signaling pathways by PPAR alpha. < / FREETEXT > < / ABSTRACT > \u2583",
  "The cell division cycle is a highly conserved process that is essential for the proliferation of all cells. The cell cycle is divided into four phases: G1, S, G2 and M, with the transition from one phase to the next being regulated by a complex network of positive and negative regulators. The transition from G1 to S phase is regulated by the cyclin-dependent kinases (CDKs), which are activated by the binding of cyclins. The activity of the CDKs is inhibited by the CDK inhibitors (CKIs). The CKIs are divided into two families, the INK4 family and the Kip / Cip family. The INK4 family includes p1 6, p1 5, p1 8 and p19, and the Kip / Cip family includes p2 1, p2 7 and p5 7. The CKIs are regulated by phosphorylation and dephosphorylation. The INK4 family members are phosphorylated by the cyclin D-CDK4 / 6 complex and are subsequently released from the complex to inhibit the cyclin E-CDK2 complex. The Kip / Cip family members are phosphorylated by the cyclin E-CDK2 complex and are released from the complex to inhibit the cyclin A-CDK2 complex. The transition from G2 to M phase is regulated by the activation of the Cdc2-cyclin B complex. The Cdc2-cyclin B complex is activated by the dephosphorylation of the inhibitory proteins by the Cdc2 5C phosphatase. The activity of the Cdc2-cyclin B complex is also regulated by the CKIs. The Cdc2 5C phosphatase is activated by the phosphorylation of an inhibitory site by the checkpoint kinases ATM and ATR. The checkpoint kinases are inhibited by the CKIs, which are activated by the checkpoint kinases. The checkpoint kinases are also regulated by phosphorylation and dephosphorylation. The checkpoint kinases are activated by the ATM and ATR kinases, which are activated by DNA damage. The checkpoint kinases phosphorylate the checkpoint kinase chk1 and chk2, which in turn phosphorylate and inhibit the Cdc2 5C phosphatase. The CKIs are also regulated by phosphorylation and dephosphorylation. The CKIs are phosphorylated by the cyclin-dependent kinases (CDKs), which inhibit their activity. The CKIs are also inhibited by the Cdc2 5C phosphatase. The checkpoint kinases are inhibited by the Wee1 kinase, which is activated by the ATM and ATR kinases. The Cdc2 5C phosphatase is activated by the dephosphorylation of the inhibitory sites by the Cdc2 5 phosphatase. The checkpoint kinases are also inhibited by the protein tyrosine phosphatase Wip1. The checkpoint kinases are also inhibited by the protein tyrosine phosphatase Pyp1. The checkpoint kinases are activated by the DNA damage response. The DNA damage response is activated by DNA damage, such as that caused by ionizing radiation. The DNA damage response is activated by the ATM kinase, which is activated by the presence of DNA damage. The ATM kinase phosphorylates chk1 and chk2, which in turn phosphorylate and activate the checkpoint kinases. The checkpoint kinases phosphorylate and inhibit Cdc2 5C, which dephosphorylates and activates the Cdc2-cyclin B complex. The CKIs are also phosphorylated by the checkpoint kinases, which inhibit their activity. The CKIs are also inhibited by the Cdc2-cyclin B complex. The CKIs are phosphorylated by the Cdc2-cyclin B complex, which inhibits their activity. The DNA damage response is activated by the presence of DNA damage, which causes the activation of the ATM kinase. The ATM kinase is activated by the presence of DNA damage, which causes the activation of the checkpoint kinases. The checkpoint kinases phosphorylate and inhibit Cdc2 5C, which dephosphorylates and activates the Cdc2-cyclin B complex. The CKIs are also phosphorylated by the Cdc2-cyclin B complex, which inhibits their activity. The checkpoint kinases are also inhibited by the protein tyrosine phosphatase Wip1, which is activated by the ATM kinase. The checkpoint kinases are also inhibited by the protein tyrosine phosphatase Pyp1, which is activated by the ATM kinase. The checkpoint kinases are also inhibited by the protein tyrosine phosphatase Wip1, which is activated by the ATM kinase. The checkpoint kinases are also inhibited by the protein tyrosine phosphatase Pyp1, which is activated by the ATM kinase. The checkpoint kinases are also inhibited by the protein tyrosine phosphatase Wip1. The checkpoint kinases are also inhibited by the protein tyrosine phosphatase Pyp1, which is activated by the ATM kinase. The checkpoint kinases are inhibited by the protein tyrosine phosphatase Wip1, which is activated by the ATM kinase. The checkpoint kinases are also inhibited by the protein tyrosine phosphatase Pyp1, which is activated by the ATM kinase. The checkpoint kinases are also inhibited by the protein tyrosine phosphatase Wip1, which is activated by the ATM kinase. The checkpoint kinases are also inhibited by the protein tyrosine phosphatase Pyp1, which is activated by the ATM kinase. The checkpoint kinases are also inhibited by the protein tyrosine phosphatase Wip1, which is activated by the ATM kinase. The checkpoint kinases are also inhibited by the protein tyrosine phosphatase Pyp1, which is activated by the ATM kinase. The checkpoint kinases are also inhibited by the protein tyrosine phosphatase Pyp1, which is activated by the ATM kinase. The checkpoint kinases are also inhibited by the protein tyrosine phosphatase Wip1, which is activated by the ATM kinase. The protein tyrosine phosphatase Wip1 is activated by the ATM kinase. The checkpoint kinases are also inhibited by the protein tyrosine phosphatase Wip1. The checkpoint kinases are also inhibited by the protein tyrosine phosphatase Pyp1, which is activated by the ATM kinase. The checkpoint kinases are also inhibited by the protein tyrosine phosphatase Pyp1, which is activated by the ATM kinase.",
  "The G-protein-coupled receptor (GPCR) superfamily is a large group of cell surface receptors that respond to a variety of extracellular stimuli. GPCRs are involved in a wide variety of physiological processes, including vision, olfaction, taste, pain, and immune response. GPCRs are also the target of many therapeutic agents. The GPCR superfamily is divided into four families: rhodopsin-like, secretin, glutamate / 5HT7, and frizzled. The rhodopsin-like family is further divided into subfamilies: alpha, beta, and gamma. The alpha subfamily includes receptors for the neurotransmitters epinephrine, dopamine, and norepinephrine. The beta subfamily includes receptors for the hormones epinephrine, norepinephrine, and lysophosphatidic acid. The gamma subfamily includes receptors for the peptides somatostatin, neuropeptide Y, and the gamma-aminobutyric acid (GABA). The glutamate / 5HT7 family includes receptors for the excitatory neurotransmitters glutamate and serotonin. The frizzled family includes receptors for the secreted glycoprotein Wnt. GPCRs are characterized by the presence of seven transmembrane domains. The extracellular domain contains the ligand binding site, and the intracellular domain couples to G proteins. G proteins are a family of GTP-binding proteins that are involved in signal transduction. The alpha subunit of the G protein is released upon receptor activation and interacts with and activates a downstream effector. The effector is usually a membrane-bound enzyme, such as adenylyl cyclase, that catalyzes the conversion of ATP to cAMP. The beta and gamma subunits of the G protein are released and interact with other proteins to form a complex that transduces the signal. The beta subunit interacts with the enzyme phosphodiesterase to inhibit its activity. The gamma subunit interacts with the enzyme protein kinase C to activate it. The beta subunit also interacts with the scaffold protein arrestin to desensitize the receptor. The beta subunit also interacts with axin to form a complex that transduces the Wnt signal. The gamma subunit interacts with the scaffold protein axin to activate the Wnt pathway.",
  "The metabolism of steroid hormones is initiated by the action of 1 7 beta-hydroxysteroid dehydrogenase (1 7 beta-HSD), which converts 4-ene-3-oxosteroids (testosterone and androstenedione) to their 5 alpha-reduced metabolites (dihydrotestosterone and androstanedione). The 5 alpha-reductase then converts the reduced steroids to their respective 5beta-reduced metabolites (androstanediol and androstanedionedione). The 5alpha-reductase also reduces the 3-keto group of 4-ene-3-oxosteroids to form the corresponding 4-enes. The 5alpha-reductase is a microsomal enzyme that is highly specific for its substrate and cofactor. The 5alpha-reductase is a member of the aldo-keto reductase (AKR) family of enzymes. The AKR1C subfamily of AKRs includes the human liver-specific aldo-keto reductase 1C1 (also known as steroid reductase I), the human prostate-specific aldo-keto reductase 1C3 (also known as steroid reductase II), and the rat liver-specific aldo-keto reductase 1C1. The AKR1B subfamily of AKRs includes the human liver-specific aldo-keto reductase 1C2 (also known as steroid reductase II) and the rat liver-specific aldo-keto reductase 1C1. The AKR1D subfamily of AKRs includes the human liver-specific aldo-keto reductase 1C4 (also known as steroid reductase II) and the rat liver-specific aldo-keto reductase 1D1. The AKR1E subfamily includes the human liver-specific aldo-keto reductase 1E1 and the rat liver-specific aldo-keto reductase 1E2. The AKR1F subfamily includes the human liver-specific aldo-keto reductase 1F3 and the rat liver-specific aldo-keto reductase 1F1. The AKR1G subfamily includes the human liver-specific aldo-keto reductase 1F3 and the rat liver-specific aldo-keto reductase 1G2. The AKR1H subfamily includes the human liver-specific aldo-keto reductase 1H3 and the rat liver-specific aldo-keto reductase 1H1. The AKR1J subfamily includes the human liver-specific aldo-keto reductase 1H4 and the rat liver-specific aldo-keto reductase 1J3. The AKR7A2 gene encodes a protein with high sequence similarity to the aldo-keto reductase 1C1. The AKR7A2 gene is located on chromosome 1 0q2 2. 1 and is transcribed from the same promoter as the AKR1C1 gene. The AKR7A2 gene is expressed in the liver and is involved in the metabolism of bile acids.",
  "The insulin-like growth factor-1 (IGF-1) receptor (IGF-1R) is a transmembrane tyrosine kinase that is activated by IGF-1 and IGF-2. IGF-1 is a potent mitogen and antiapoptotic factor. IGF-1 is produced in the liver and is secreted into the blood. IGF-1 is transported to target tissues by IGF-1 binding proteins (IGFBPs). IGFBPs are a family of proteins that bind IGF-1 with high affinity and regulate its bioavailability. The IGF-1 / IGF-1R system is involved in the regulation of growth and development, and in the regulation of glucose homeostasis. IGF-1 is also involved in the development of cancer and in the response of cancer cells to chemotherapy. The IGF-1 / IGF-1R system is activated in many types of cancer, including breast, prostate, and colon cancer. IGF-1 stimulates cell proliferation and inhibits apoptosis. The IGF-1 / IGF-1R system also plays a role in the development of obesity and insulin resistance. The IGF-1 / IGF-1R system is a potential target for cancer therapy and for the treatment of diabetes. The IGF-1 / IGF-1R system is also a potential target for the prevention of obesity and type 2 diabetes. The IGF-1 / IGF-1R system is activated by binding of IGF-1 to the IGF-1R. IGF-1 binding to the IGF-1R activates the intrinsic tyrosine kinase activity of the IGF-1R, which phosphorylates the IGF-1R and other substrates. The phosphorylated IGF-1R recruits and activates intracellular signaling pathways, including the PI3 kinase / Akt pathway, that regulate cell proliferation and survival.",
  "The epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptor tyrosine kinases. Binding of ligands to the extracellular domain of EGFR leads to receptor dimerization and activation of the intrinsic tyrosine kinase domain. This results in the recruitment of signaling molecules to the cell surface and activation of downstream signaling pathways that regulate cell proliferation, differentiation, and survival. EGFR is overexpressed in many human cancers, and is associated with a poor prognosis. EGFR inhibitors are being evaluated as cancer therapies.",
  "The integrin family of cell adhesion receptors is involved in a variety of cellular processes including cell migration, cell spreading, and cell proliferation. The cytoplasmic domains of the integrin alpha and beta subunits are involved in the regulation of these processes. The integrin beta subunit cytoplasmic domain is involved in the regulation of integrin affinity for ligand and in the regulation of integrin clustering. The integrin alpha subunit cytoplasmic domain is involved in the regulation of integrin affinity for ligand and in the regulation of integrin clustering. The integrin cytoplasmic domains are involved in the regulation of integrin affinity for ligand by a variety of mechanisms including regulation of integrin clustering and regulation of the affinity of the extracellular domain for ligand. The integrin cytoplasmic domains are also involved in the regulation of integrin signaling. The integrin cytoplasmic domains are involved in the regulation of integrin signaling by a variety of mechanisms including regulation of integrin affinity for ligand, regulation of integrin clustering, and regulation of the affinity of the extracellular domain for ligand. The integrin cytoplasmic domains are also involved in the regulation of integrin signaling. The integrin cytoplasmic domains are involved in the regulation of integrin signaling by a variety of mechanisms including regulation of integrin affinity for ligand, regulation of integrin clustering, and regulation of the affinity of the extracellular domain for ligand. The integrin cytoplasmic domains are involved in the regulation of integrin signaling by a variety of mechanisms including regulation of integrin affinity for ligand, regulation of integrin clustering, and regulation of the affinity of the extracellular domain for ligand. The integrin cytoplasmic domains are involved in the regulation of integrin signaling by a variety of mechanisms including regulation of integrin affinity for ligand, regulation of integrin clustering, and regulation of the affinity of the extracellular domain for ligand. The integrin cytoplasmic domains are involved in the regulation of integrin signaling by a variety of mechanisms including regulation of integrin clustering and regulation of the affinity of the extracellular domain for ligand. The integrin cytoplasmic domains are involved in the regulation of integrin signaling by a variety of mechanisms including regulation of integrin affinity for ligand, regulation of integrin clustering, and regulation of the affinity of the extracellular domain for ligand. The integrin cytoplasmic domains are involved in the regulation of integrin signaling by a variety of mechanisms including regulation of integrin affinity for ligand, regulation of integrin clustering, and regulation of the affinity of the extracellular domain for ligand.",
  "Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the selective loss of dopaminergic (DA) neurons in the substantia nigra (SN). Although the etiology of PD is still unclear, genetic and environmental factors are thought to be involved in the pathogenesis of PD. The discovery of genes linked to familial PD has provided important insights into the pathogenesis of PD. Mutations in the alpha-synuclein (SNCA), parkin (PARK2), PTEN induced putative kinase 1 (PINK1), and DJ-1 (PARK7) genes are associated with autosomal dominant forms of PD. In addition, mutations in leucine-rich repeat kinase 2 (LRRK2) are associated with both autosomal dominant and sporadic forms of PD. These genes are involved in a variety of cellular functions, including mitochondrial function, oxidative stress, protein misfolding, and protein degradation. Environmental factors, such as exposure to pesticides and metals, are also thought to contribute to the etiology of PD. These factors may cause oxidative stress, mitochondrial dysfunction, and protein misfolding, which may lead to the selective loss of DA neurons. < / FREETEXT > < / ABSTRACT > \u2583",
  "The kallikrein-kinin system is a group of serine proteases and their specific inhibitors, the serpins. The kallikrein-kinin system is involved in a variety of biological processes, including blood pressure regulation, inflammation, and pain. The kallikrein-kinin system is activated by tissue kallikrein, which cleaves high molecular weight kininogen to release bradykinin. Bradykinin is a potent vasodilator and proinflammatory peptide that acts through two G-protein coupled receptors, B1and B2. The B1receptor is constitutively expressed in many tissues and is involved in the inflammatory response. The B2receptor is induced by inflammatory stimuli and is involved in pain signaling. The B1receptor is also activated by kallidin, a bradykinin-like peptide found in the salivary glands of many species. The B1receptor is activated by kallidin, but not bradykinin, and the B2receptor is not activated by kallidin. Kinin is degraded by the protease ACE, and ACE inhibitors are used to treat hypertension and heart failure. The ACE inhibitors block the breakdown of bradykinin and the B1receptor agonist kallidin, and increase the activity of the B1receptor. The B1receptor is also activated by des-Arg-bradykinin, a kinin peptide that is not degraded by ACE. The des-Arg-bradykinin B1receptor agonist is a potent vasodilator and proinflammatory peptide that is increased in patients with ACE inhibitors. The ACE inhibitors block the breakdown of des-Arg-bradykinin, increasing the activity of the B1receptor. The ACE inhibitors also increase the activity of the B1receptor through a mechanism that is not yet understood. The ACE inhibitors are also used to treat heart failure, and the increase in B1receptor activity may contribute to the beneficial effects of these drugs.",
  "The metabotropic glutamate receptors (mGluRs) are a family of G-protein coupled receptors (GPCRs) that respond to the neurotransmitter glutamate. The mGluRs are divided into three groups based on their sequence homology, agonist pharmacology and signal transduction mechanisms. Group I mGluRs (mGluR1 and mGluR5) are coupled to the Gq / 1 1 family of G-proteins and activate phospholipase C (PLC) through the activation of the alpha subunit of Gq / 1 1. The activation of PLC results in the production of IP3 and DAG, which in turn stimulate the release of intracellular calcium and activate protein kinase C (PKC), respectively. The activation of PKC also leads to the activation of the MAP kinase cascade. Group II mGluRs (mGluR2 and mGluR3) are coupled to the Gi / o family of G-proteins and inhibit adenylyl cyclase (AC) activity. The activation of Gi / o also leads to the inhibition of voltage-gated calcium channels and the activation of potassium channels. The activation of Gi / o also leads to the activation of the MAP kinase cascade. Group III mGluRs (mGluR4, mGluR6, mGluR7 and mGluR8) are not coupled to G-proteins and are negatively coupled to adenylyl cyclase (AC). The activation of mGluRs leads to the inhibition of voltage-gated calcium channels and the activation of potassium channels.",
  "Acute myeloid leukemia (AML) is a heterogeneous disease with respect to clinical presentation, morphology, cytogenetics, and molecular genetics. The majority of AML cases are classified as de novo AML, which is diagnosed in patients without a history of a previous hematologic disorder. Secondary AML (sAML) develops from a preleukemic condition, such as a myelodysplastic syndrome (MDS), or may be associated with a previous cytotoxic therapy. The incidence of AML is approximately 3-5 cases per 1 0 0, 0 0 0 persons per year. AML is a clonal disorder of hematopoietic stem cells (HSCs) or early progenitor cells. The hallmark of AML is the presence of immature myeloid cells in the bone marrow and peripheral blood. The immature myeloid cells are blocked at various stages of differentiation, and are unable to differentiate into mature neutrophils, erythrocytes, or macrophages. The blasts in AML are characterized by a high proliferative rate and a low level of apoptosis. The blasts in AML are heterogeneous in their morphology, and can be identified by their expression of cell surface antigens. The French-American-British (FAB) classification system is used to classify AML into subtypes based on the percentage of blasts in the bone marrow and peripheral blood. The FAB subtypes are M0, M1, M2, M3, M4, and M5. The most common subtype is acute promyelocytic leukemia (APL), which is characterized by the presence of the PML-RARA fusion gene. The prognosis of AML is dependent on the type of AML and the patient's age. The overall survival of patients with AML is poor, with a 5-year survival rate of less than 3 0%. The treatment of AML is based on the use of chemotherapy, which is the current standard of care for patients with AML. The use of intensive chemotherapy has improved the outcome of patients with AML. The addition of the anthracycline idarubicin to the standard 7 + 3 regimen (cytosine arabinoside and an anthracycline) has improved the complete remission (CR) rate and overall survival (OS) in patients with newly diagnosed AML. The addition of the topoisomerase II inhibitor, etoposide, to the standard 7 + 3 regimen has improved the CR rate and OS in patients with relapsed or refractory AML. The use of hematopoietic growth factors (HGFs) may improve the outcome of patients with AML. GFs stimulate the proliferation and differentiation of hematopoietic cells. The use of GFs in combination with chemotherapy may improve the outcome of patients with AML.",
  "The development of cancer is a multistep process that involves the accumulation of multiple genetic alterations. The inactivation of tumor suppressor genes and the activation of oncogenes are two of the most common mechanisms by which cancer cells are generated. The tumor suppressor gene p53 is one of the most frequently mutated genes in human cancer. The p53 gene encodes a protein that is involved in cell cycle regulation and apoptosis. The p53 protein is activated by a variety of cellular stresses, including DNA damage, oxidative stress, and activated oncogenes. Upon activation, p53 induces cell cycle arrest and apoptosis. The p53 gene is mutated in many human cancers, including colon, breast, and lung cancer. The p53 gene is also inactivated by promoter methylation in many other cancers. The p53 gene is also a transcriptional target of the tumor suppressor gene p54. The p53 protein interacts with a variety of cellular proteins to regulate cell cycle progression and apoptosis. The p53 protein also interacts with the tumor suppressor protein p54 to induce apoptosis. The p53 protein also interacts with the MDM2 protein to regulate the stability of the p53 protein. The p53 protein is also a transcriptional activator of the p54 gene. The p53 protein interacts with the transcription factor YY1 to activate the p54 gene. The p53 protein also interacts with the transcription factor Ets2 to activate the p53 gene. The p53 protein also interacts with the tumor suppressor protein p73 to activate the p53 gene. The p53 protein also interacts with the tumor suppressor protein p73 to induce apoptosis. The p53 protein also interacts with the tumor suppressor protein p73 to induce apoptosis. The p53 protein interacts with the tumor suppressor protein p73 to induce apoptosis. The p53 protein also interacts with the tumor suppressor protein p73 to induce apoptosis.",
  "Leukocyte trafficking from the blood into tissues is a highly regulated process that is essential for the normal functioning of the immune system. The first step in this process is the rolling of leukocytes along the vascular endothelium of the blood vessel wall. This is mediated by the interaction of selectins on the leukocyte with ligands on the vascular endothelium. The rolling step is followed by firm adhesion of the leukocyte to the vascular endothelium, mediated by the interaction of integrins on the leukocyte with ligands on the vascular endothelium. The leukocytes then transmigrate through the endothelial cell layer and into the tissue. The rolling step is mediated by the interaction of selectins on the leukocyte with their ligands on the vascular endothelium. The selectins are a family of three carbohydrate-binding proteins expressed on the surface of leukocytes. P-selectin is expressed on the surface of activated platelets and endothelial cells. L-selectin is expressed on the surface of leukocytes and is constitutively expressed on the surface of lymphocytes. E-selectin is expressed on the surface of endothelial cells in inflamed tissues. The selectin-ligand interaction is highly specific and requires the presence of a specific carbohydrate structure on the selectin ligand and a specific carbohydrate structure on the selectin. The selectin ligands on leukocytes include PSGL-1, a mucin-like glycoprotein that is expressed on the surface of leukocytes. PSGL-1 is the ligand for P- and E-selectin. The selectin ligands on endothelial cells include a sialomucin, MAdCAM-1, and a sulfated carbohydrate, sulfomucin. The selectin ligands on leukocytes include PSGL-1 and a sialomucin, CD4 4. The interaction of selectins with their ligands on leukocytes is a key step in the rolling of leukocytes along the vascular endothelium. The rolling step is followed by firm adhesion of the leukocyte to the vascular endothelium. The firm adhesion of leukocytes is mediated by the interaction of integrins on the leukocyte with their ligands on the vascular endothelium. The interaction of selectins with their ligands on leukocytes is a key step in the rolling of leukocytes along the vascular endothelium. The interaction of selectins with their ligands on leukocytes is a key step in the rolling of leukocytes along the vascular endothelium. The interaction of selectins with their ligands on leukocytes is a key step in the rolling of leukocytes along the vascular endothelium. The rolling step is followed by firm adhesion of the leukocyte. The firm adhesion of leukocytes is mediated by the interaction of integrins on the leukocyte with their ligands on the vascular endothelium. The interaction of selectins with their ligands on leukocytes is a key step in the rolling of leukocytes along the vascular endothelium. The interaction of selectins with their ligands on leukocytes is a key step in the rolling of leukocytes along the vascular endothelium. The interaction of selectins with their ligands on leukocytes is a key step in the rolling of leukocytes along the vascular endothelium. The rolling of leukocytes along the vascular endothelium is a key step in the rolling of leukocytes along the vascular endothelium. The rolling step is mediated by the interaction of selectins with their ligands on the vascular endothelium. The selectin ligands on the vascular endothelium include a sialomucin, MAdCAM-1, and a sulfated carbohydrate, sulfomucin. The selectin ligands on leukocytes include PSGL-1 and CD4 4. The interaction of selectins with their ligands on leukocytes is a key step in the rolling of leukocytes along the vascular endothelium. The interaction of selectins with their ligands is a key step in the rolling of leukocytes along the vascular endothelium. The rolling step is followed by firm adhesion of the leukocyte to the vascular endothelium. The firm adhesion of leukocytes is mediated by the interaction of integrins on the leukocyte with their ligands on the vascular endothelium. The interaction of selectins with their ligands on leukocytes is a key step in the rolling of leukocytes along the vascular endothelium. The interaction of selectins with their ligands on leukocytes is a key step in the rolling of leukocytes along the vascular endothelium. The interaction of selectins with their ligands on leukocytes is a key step in the rolling of leukocytes along the vascular endothelium.",
  "The nucleolus is the site of ribosome biogenesis in eukaryotes. Ribosome biogenesis is a complex process that requires the coordinated expression of genes encoding ribosomal RNA (rRNA), ribosomal proteins (RPs) and other factors involved in ribosome assembly. The transcription of rDNA by RNA polymerase I (Pol I) is the first step in ribosome biogenesis. The transcription of rDNA by Pol I is tightly regulated by a variety of factors, including the upstream binding factor (UBF), the TATA-binding protein (TBP), and the upstream binding factor-associated factors (UBF-associated factors). The transcription of rDNA by Pol I is also regulated by the tumor suppressor protein, p53. The tumor suppressor protein, p53, is a negative regulator of Pol I transcription. The tumor suppressor protein, p53, interacts with the TBP-associated factor, TAFI4 8, and inhibits the formation of the UBF-TBP-TAFI4 8 complex. The tumor suppressor protein, p53, also interacts with the RNA polymerase I complex and inhibits the initiation of Pol I transcription. The tumor suppressor protein, p53, is a negative regulator of Pol I transcription. The tumor suppressor protein, p53, is a negative regulator of Pol I transcription. The tumor suppressor protein, p53, is a negative regulator of Pol I transcription. The tumor suppressor protein, p53, is a negative regulator of Pol I transcription. The tumor suppressor protein, p53, is a negative regulator of Pol I transcription. The tumor suppressor protein, p53, is a negative regulator of Pol I transcription. The tumor suppressor protein, p53, is a negative regulator of Pol I transcription. The tumor suppressor protein, p53, is a negative regulator of Pol I transcription. The tumor suppressor protein, p53, is a negative regulator of Pol I transcription. The tumor suppressor protein, p53, is a negative regulator of Pol I transcription. The tumor suppressor protein, p53, is a negative regulator of Pol I transcription. The tumor suppressor protein, p53, is a negative regulator of Pol I transcription.",
  "The FA pathway is required for the repair of DNA interstrand crosslinks (ICLs). The FA pathway is also involved in the repair of DNA double-strand breaks (DSBs). The FA pathway is activated by DNA damage and replication stress. The FA core complex is required for the monoubiquitination of the FANCD2 and FANCI proteins. The monoubiquitinated FANCD2 and FANCI proteins form nuclear foci at the sites of DNA damage and are required for the repair of ICLs and DSBs. The FA core complex is composed of eight FA proteins (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, and FANCM). The FA core complex is required for the monoubiquitination of FANCD2 and FANCI. The FANCM protein is a DNA translocase that is required for the monoubiquitination of FANCD2 and FANCI. The FANCM-associated protein (FAAP1 0 0) is required for the monoubiquitination of FANCD2 and FANCI. The FANCM-associated histone fold protein 2 (MHF2) is also required for the monoubiquitination of FANCD2 and FANCI. The FAN1 nuclease is also required for the monoubiquitination of FANCD2 and FANCI. The FANCM-associated nuclease 1 (FAN1) is a DNA structure-specific endonuclease that is required for the monoubiquitination of FANCD2 and FANCI. The FAN1 nuclease also plays a role in the repair of DNA ICLs. The breast cancer susceptibility gene product BRCA2 is also required for the monoubiquitination of FANCD2 and FANCI. The BRCA2 protein interacts with the FANCM-associated protein (FAAP2 0) to form a complex that is required for the monoubiquitination of FANCD2 and FANCI. The BRCA2 protein interacts with RAD5 1 to form a complex that is required for homologous recombination repair.",
  "The biosynthesis of chondroitin sulfate chains begins with the transfer of N-acetylgalactosamine (GalNAc) from UDP-GalNAc to the serine or threonine residue of a polypeptide to form GalNAc- (Ser / Thr). The first reaction in the pathway is catalyzed by the chondroitin synthase (chondroitin polymerizing factor, ChPF). ChPF is a bifunctional enzyme that catalyzes the transfer of GalNAc from UDP-GalNAc to the hydroxyl group of serine or threonine to form GalNAc- (Ser / Thr). The next reaction is catalyzed by chondroitin synthase (chondroitin sulfate N-acetylgalactosaminyltransferase, CSGALNT), which transfers sulfate from PAPS to position 6 of the GalNAc residue to form GalNAc- (4O-sulfate) -Ser / Thr. The next two reactions are catalyzed by chondroitin sulfate epimerase (chondroitin C-5-epimerase, EC 5. 1.3. 1 0) and chondroitin sulfate sulfotransferase (chondroitin sulfotransferase, EC 2. 8.2. 2). The chondroitin sulfate N-acetylgalactosaminyltransferase (chondroitin synthase) is a membrane-bound enzyme that is localized in the Golgi apparatus. The chondroitin sulfate N-acetylgalactosaminyltransferase transfers sulfate from PAPS to position 4 of the GalNAc residue to form chondroitin. The chondroitin sulfate sulfotransferase transfers sulfate from PAPS to position 6 of the GalNAc residue to form chondroitin 4-sulfate. The chondroitin sulfate C-5-epimerase catalyzes the conversion of chondroitin to chondroitin 5-sulfate. The chondroitin sulfate C-5-epimerase catalyzes the conversion of chondroitin to dermatan sulfate. The chondroitin sulfate N-acetylgalactosaminyltransferase, chondroitin sulfate C-5-epimerase, and chondroitin sulfate sulfotransferase are all soluble enzymes that are localized in the cytosol. The chondroitin sulfate N-acetylgalactosaminyltransferase transfers sulfate from PAPS to position 4 of the GalNAc residue to form GalNAc 4-sulfate. The chondroitin sulfate C-5-epimerase catalyzes the conversion of chondroitin to chondroitin sulfate. The chondroitin sulfate sulfotransferase catalyzes the transfer of sulfate from PAPS to position 6 of the GalNAc residue to form chondroitin 6-sulfate. The chondroitin sulfate sulfotransferase also transfers sulfate from PAPS to position 2 of the GalNAc residue to form chondroitin 2-sulfate. The chondroitin sulfate N-acetylgalactosaminyltransferase, chondroitin sulfate C-5-epimerase, and chondroitin sulfate sulfotransferase are all soluble enzymes that are localized in the cytosol. The chondroitin sulfate N-acetylgalactosaminyltransferase, chondroitin sulfate C-5-epimerase, and chondroitin sulfate sulfotransferase are all soluble enzymes that are localized in the cytosol. The chondroitin sulfate N-acetylgalactosaminyltransferase, chondroitin sulfate C-5-epimerase, and chondroitin sulfate sulfotransferase are all soluble enzymes that are localized in the cytosol. The chondroitin sulfate N-acetylgalactosaminyltransferase, chondroitin sulfate C-5-epimerase, and chondroitin sulfate sulfotransferase are all soluble enzymes that are localized in the cytosol. The chondroitin sulfate N-acetylgalactosaminyltransferase, chondroitin sulfate C-5-epimerase, and chondroitin sulfate sulfotransferase are all soluble enzymes that are localized in the cytosol. The chondroitin sulfate N-acetylgalactosaminyltransferase, chondroitin sulfate C-5-epimerase, and chondroitin sulfate sulfotransferase are all soluble enzymes that are localized in the cytosol. The chondroitin sulfate N-acetylgalactosaminyltransferase, chondroitin sulfate C-5-epimerase, and chondroitin sulfate sulfotransferase are all soluble enzymes that are localized in the cytosol. The chondroitin sulfate N-acetylgalactosaminyltransferase, chondroitin sulfate C-5-epimerase, and chondroitin sulfate sulfotransferase are all soluble enzymes that are localized in the cytosol. The chondroitin sulfate N-acetylgalactosaminyltransferase, chondroitin sulfate C-5-epimerase, and chondroitin sulfate sulfotransferase are all soluble enzymes that are localized in the cytosol. The chondroitin sulfate N-acetylgalactosaminyltransferase, chondroitin sulfate C-5-epimerase, and chondroitin sulfate sulfotransferase are all soluble enzymes that are localized in the cytosol. The chondroitin sulfate N-acetylgalactosaminyltransferase, chondroitin sulfate C-5-epimerase, and chondroitin sulfate sulfotransferase are all soluble enzymes that are localized in the cytosol. The chondroitin sulfate N-acetylgalactosaminyltransferase, chondroitin sulfate C-5-epimerase, and chondroitin sulfate sulfotransferase are all soluble enzymes that are localized in the cytosol. The chondroitin sulfate N-acetylgalactosaminyltransferase, chondroitin sulfate C-5-epimerase, and chondroitin sulfate sulfotransferase are all soluble enzymes that are localized in the cytosol. The chondroitin sulfate N-acetylgalactosaminyltransferase, chondroitin sulfate C-5-epimerase, and chondroitin sulfate sulfotransferase are all soluble enzymes that are localized in the cytosol. The chondroitin sulfate N-acetylgalactosaminyltransferase, chondroitin sulfate C-5-epimerase, and chondroitin sulfate sulfotransferase are all soluble enzymes that are localized in the cytosol. The chondroitin sulfate N-acetylgalactosaminyltransferase, chondroitin sulfate C-5-epimerase, and chondroitin sulfate sulfotransferase are all soluble enzymes that are localized in the cytosol. The chondroitin sulfate N-acetylgalactosaminyltransferase, chondroitin sulfate C-5-epimerase, and chondroitin sulfate sulfotransferase are all soluble enzymes that are localized in the cytosol.",
  "Apoptosis is a genetically programmed cell death that is essential for the development and homeostasis of multicellular organisms. The apoptotic pathway is initiated by a variety of stimuli including DNA damage, growth factor withdrawal, and other cellular stresses. The apoptotic signal is transmitted through the mitochondria and the caspase cascade. The Bcl-2 family of proteins regulates the mitochondrial apoptotic pathway. The Bcl-2 family includes both anti-apoptotic and pro-apoptotic members. The anti-apoptotic Bcl-2 family members include Bcl-2, Bcl-xL, and Mcl-1. The pro-apoptotic Bcl-2 family members include Bax, Bak, Bad, Bid, Bik, and Bok. The Bcl-2 family members regulate the mitochondrial apoptotic pathway by controlling the release of cytochrome c from the mitochondria. Cytochrome c interacts with Apaf-1 and caspase 9 to activate caspase 3 and other caspases. The Bcl-2 family members are regulated by phosphorylation, subcellular localization, and protein-protein interactions."
]